Enoxaparin: Low-molecular-weight fragment of heparin, having a 4-enopyranosuronate sodium structure at the non-reducing end of the chain. It is prepared by depolymerization of the benzylic ester of porcine mucosal heparin. Therapeutically, it is used as an antithrombotic agent. (From Merck Index, 11th ed)Anticoagulants: Agents that prevent clotting.Heparin: A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts.Venous Thromboembolism: Obstruction of a vein or VEINS (embolism) by a blood clot (THROMBUS) in the blood stream.Factor Xa: Activated form of factor X that participates in both the intrinsic and extrinsic pathways of blood coagulation. It catalyzes the conversion of prothrombin to thrombin in conjunction with other cofactors.Hemorrhage: Bleeding or escape of blood from a vessel.Fibrinolytic Agents: Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN.Heparin, Low-Molecular-Weight: Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of hemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism.Thromboembolism: Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream.Venous Thrombosis: The formation or presence of a blood clot (THROMBUS) within a vein.Injections, Subcutaneous: Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin.Nadroparin: A heparin fraction with a mean molecular weight of 4500 daltons. It is isolated from porcine mucosal heparin and used as an antithrombotic agent. (From Merck Index, 11th ed)Partial Thromboplastin Time: The time required for the appearance of FIBRIN strands following the mixing of PLASMA with phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides). It is a test of the intrinsic pathway (factors VIII, IX, XI, and XII) and the common pathway (fibrinogen, prothrombin, factors V and X) of BLOOD COAGULATION. It is used as a screening test and to monitor HEPARIN therapy.ThiophenesAngina, Unstable: Precordial pain at rest, which may precede a MYOCARDIAL INFARCTION.Pulmonary Embolism: Blocking of the PULMONARY ARTERY or one of its branches by an EMBOLUS.Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)Thrombophlebitis: Inflammation of a vein associated with a blood clot (THROMBUS).Double-Blind Method: A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.Blood Coagulation: The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Platelet Glycoprotein GPIIb-IIIa Complex: Platelet membrane glycoprotein complex important for platelet adhesion and aggregation. It is an integrin complex containing INTEGRIN ALPHAIIB and INTEGRIN BETA3 which recognizes the arginine-glycine-aspartic acid (RGD) sequence present on several adhesive proteins. As such, it is a receptor for FIBRINOGEN; VON WILLEBRAND FACTOR; FIBRONECTIN; VITRONECTIN; and THROMBOSPONDINS. A deficiency of GPIIb-IIIa results in GLANZMANN THROMBASTHENIA.Tolmetin: A non-steroidal anti-inflammatory agent (ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL) similar in mode of action to INDOMETHACIN.Pyridones: Pyridine derivatives with one or more keto groups on the ring.Myocardial Infarction: NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).Drug Therapy, Combination: Therapy with two or more separate preparations given for a combined effect.Intracranial Hemorrhage, Traumatic: Bleeding within the SKULL induced by penetrating and nonpenetrating traumatic injuries, including hemorrhages into the tissues of CEREBRUM; BRAIN STEM; and CEREBELLUM; as well as into the epidural, subdural and subarachnoid spaces of the MENINGES.Antithrombins: Endogenous factors and drugs that directly inhibit the action of THROMBIN, usually by blocking its enzymatic activity. They are distinguished from INDIRECT THROMBIN INHIBITORS, such as HEPARIN, which act by enhancing the inhibitory effects of antithrombins.Platelet Aggregation Inhibitors: Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.Spinal Puncture: Tapping fluid from the subarachnoid space in the lumbar region, usually between the third and fourth lumbar vertebrae.Anesthesia, Spinal: Procedure in which an anesthetic is injected directly into the spinal cord.Pharmacology, Clinical: The branch of pharmacology that deals directly with the effectiveness and safety of drugs in humans.Spinal Cord: A cylindrical column of tissue that lies within the vertebral canal. It is composed of WHITE MATTER and GRAY MATTER.Analgesia, Epidural: The relief of pain without loss of consciousness through the introduction of an analgesic agent into the epidural space of the vertebral canal. It is differentiated from ANESTHESIA, EPIDURAL which refers to the state of insensitivity to sensation.Clot Retraction: Retraction of a clot resulting from contraction of PLATELET pseudopods attached to FIBRIN strands. The retraction is dependent on the contractile protein thrombosthenin. Clot retraction is used as a measure of platelet function.Fibrin: A protein derived from FIBRINOGEN in the presence of THROMBIN, which forms part of the blood clot.Fibrinolysis: The natural enzymatic dissolution of FIBRIN.Pregnancy: The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.Molluginaceae: A plant family of the order Caryophyllales, subclass Caryophyllidae, class Magnoliopsida. Some members contain triterpenoid saponins.Cerium: An element of the rare earth family of metals. It has the atomic symbol Ce, atomic number 58, and atomic weight 140.12. Cerium is a malleable metal used in industrial applications.Fat Body: A nutritional reservoir of fatty tissue found mainly in insects and amphibians.Drug Industry: That segment of commercial enterprise devoted to the design, development, and manufacture of chemical products for use in the diagnosis and treatment of disease, disability, or other dysfunction, or to improve function.Sodium: A member of the alkali group of metals. It has the atomic symbol Na, atomic number 11, and atomic weight 23.Architectural Accessibility: Designs for approaching areas inside or outside facilities.Vulvodynia: Complex pain syndrome with unknown etiology, characterized by constant or intermittent generalized vulva pain (Generalized vulvodynia) or localized burning sensations in the VESTIBULE area when pressure is applied (Vestibulodynia, or Vulvar Vestibulitis Syndrome). Typically, vulvar tissue with vulvodynia appears normal without infection or skin disease. Vulvodynia impacts negatively on a woman's quality of life as it interferes with sexual and daily activities.Vulvar Diseases: Pathological processes of the VULVA.Internet: A loose confederation of computer communication networks around the world. The networks that make up the Internet are connected through several backbone networks. The Internet grew out of the US Government ARPAnet project and was designed to facilitate information exchange.Physician-Patient Relations: The interactions between physician and patient.Research Personnel: Those individuals engaged in research.Vulvar Vestibulitis: Inflammation of the vulvar vestibular region at the entrance of the VAGINA, generally involving surface mucosa and submucosal vestibular glands. It is characterized by ERYTHEMA and chronic recurrent pain in this area.Drug Information Services: Services providing pharmaceutic and therapeutic drug information and consultation.Drug Overdose: Accidental or deliberate use of a medication or street drug in excess of normal dosage.Drug Interactions: The action of a drug that may affect the activity, metabolism, or toxicity of another drug.

Heparin and enoxaparin enhance endotoxin-induced tumor necrosis factor-alpha production in human monocytes. (1/358)

OBJECTIVE: To determine whether heparin or the low-molecular-weight heparin enoxaparin alter lipopolysaccharide (LPS)-induced monocyte activation. SUMMARY BACKGROUND DATA: Heparin is widely used in clinical practice to inhibit the coagulation cascade. However, heparin also is a naturally occurring glucosaminoglycan and a pleiotropic immunomodulator that binds to a variety of proteins. LPS is a component of gram-negative bacteria and is thought to be responsible for many of the deleterious effects seen in sepsis. The binding of LPS to CD14 induces a signaling cascade that results in the release of many inflammatory mediators, including tumor necrosis factor-alpha (TNF-alpha). METHODS: Monocytes from healthy volunteers were isolated and cultured in the presence of saline, LPS (10 ng/ml), heparin (0.1 to 1000 microg/ml), or enoxaparin (0.1 to 1000 microg/ml). In blocking experiments, cells were pretreated for 60 minutes with the monoclonal anti-CD14 antibody MY4 (10 microg/ml) or with isotype-matched control IgG2 (10 microg/ml). TNF-alpha values were measured with enzyme-linked immunosorbent assay. Significance was assessed with analysis of variance. RESULTS: Heparin (10 to 1000 microg/ml) and enoxaparin (1000 microg/ml) significantly enhanced LPS-induced TNF-alpha release. Heparin (1000 microg/ml) or enoxaparin (1000 microg/ml) did not produce TNF-alpha in the absence of LPS. Blockade of CD14 abrogated both LPS-induced TNF-alpha release and the effect of heparin or enoxaparin to enhance LPS-induced TNF-alpha release. CONCLUSIONS: The effect of heparin to enhance LPS-induced TNF-alpha release is a biologic phenomenon that reveals a novel and potentially important host defense mechanism during endotoxemia and sepsis. Binding of LPS to CD14 is necessary to induce this phenomenon, suggesting that both heparin and enoxaparin induce signaling mechanisms that are downstream from the initial binding of LPS on CD14.  (+info)

Epidural haematoma after removal of an epidural catheter in a patient receiving high-dose enoxaparin. (2/358)

A patient developed an epidural haematoma 6 days after removal of an epidural catheter resulting in paraplegia and death. Insertion and removal of the epidural catheter during anticoagulation with prophylactic unfractionated heparin and subsequent administration of high-dose enoxaparin (Clexane), which commenced 3 days after catheter removal, were implicated.  (+info)

Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis. (3/358)

PURPOSE: The primary objective of this study was to evaluate with venography the rate of thrombus regression after a fixed dose of low-molecular weight heparin (LMWH) per day for 3 months compared with oral anticoagulant therapy for deep venous thrombosis (DVT). Secondary endpoints were the comparisons of the efficacy and safety of both treatments. METHODS: This study was designed as an open randomized clinical study in a university hospital setting. Of the 165 patients finally enrolled in the study, 85 were assigned LMWH therapy and 80 were assigned oral anticoagulant therapy. In the group randomized to oral anticoagulant therapy, the patients first underwent treatment in the hospital with standard unfractionated heparin and then coumarin for 3 months. Doses were adjusted with laboratory monitoring to maintain the international normalized ratio between 2.0 and 3.0. Patients in the LMWH group were administered subcutaneous injections of fixed doses of 40 mg enoxaparin (4000 anti-Xa units) every 12 hours for 7 days, and after discharge from the hospital, they were administered 40 mg enoxaparin once daily at fixed doses for 3 months without a laboratory control assay. A quantitative venographic score (Marder score) was used to assess the extent of the venous thrombosis, with 0 points indicating no DVT and 40 points indicating total occlusion of all deep veins. The rate of thrombus reduction was defined as the difference in quantitative venographic scores after termination of LMWH or coumarin therapy as compared with the scores obtained on the initial venographic results. The efficacy was defined as the ability to prevent symptomatic extension or recurrence of venous thromboembolism (documented with venograms or serial lung scans). The safety was defined as the occurrence of hemorrhages. RESULTS: After 3 months of treatment, the mean Marder score was significantly decreased in both groups in comparison with the baseline score, although the effect of therapy was significantly better after LMWH therapy (49.4% reduction) than after coumarin therapy (24.5% reduction; P <.001). LMWH therapy and male gender were independently associated with an enhanced resolution of the thrombus. A lower frequency of symptomatic recurrent venous thromboembolism was also shown in patients who underwent treatment with LMWH therapy (9.5%) than with oral anticoagulant therapy (23.7%; P <.05), although this difference was entirely a result of recurrence of DVT. Bleeding complications were significantly fewer in the LMWH group than in the coumarin group (1. 1% vs 10%; P <.05). This difference was caused by minor hemorrhages. Coumarin therapy and cancer were independently associated with an enhanced risk of complications. Subcutaneous heparin therapy was well tolerated by all patients. CONCLUSION: The patients who were allocated to undergo enoxaparin therapy had a significantly greater improvement in their quantitative venographic score, a significantly lower recurrence rate of symptomatic venous thromboembolism, and a significantly lower incidence of bleeding than patients who underwent treatment with coumarin. LMWH can be used on an outpatient basis as a safer and more effective alternative to classical oral anticoagulant therapy for the secondary prophylaxis of selected patients with DVT.  (+info)

A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. (4/358)

BACKGROUND: The efficacy and safety of thromboprophylaxis in patients with acute medical illnesses who may be at risk for venous thromboembolism have not been determined in adequately designed trials. METHODS: In a double-blind study, we randomly assigned 1102 hospitalized patients older than 40 years to receive 40 mg of enoxaparin, 20 mg of enoxaparin, or placebo subcutaneously once daily for 6 to 14 days. Most patients were not in an intensive care unit. The primary outcome was venous thromboembolism between days 1 and 14, defined as deep-vein thrombosis detected by bilateral venography (or duplex ultrasonography) between days 6 and 14 (or earlier if clinically indicated) or documented pulmonary embolism. The duration of follow-up was three months. RESULTS: The primary outcome could be assessed in 866 patients. The incidence of venous thromboembolism was significantly lower in the group that received 40 mg of enoxaparin (5.5 percent [16 of 291 patients]) than in the group that received placebo (14.9 percent [43 of 288 patients]) (relative risk, 0.37; 97.6 percent confidence interval, 0.22 to 0.63; P< 0.001). The benefit observed with 40 mg of enoxaparin was maintained at three months. There was no significant difference in the incidence of venous thromboembolism between the group that received 20 mg of enoxaparin (43 of 287 patients [15.0 percent]) and the placebo group. The incidence of adverse effects did not differ significantly between the placebo group and either enoxaparin group. By day 110, 50 patients had died in the placebo group (13.9 percent), 51 had died in the 20-mg group (14.7 percent), and 41 had died in the 40-mg group (11.4 percent); the differences were not significant. CONCLUSIONS: Prophylactic treatment with 40 mg of enoxaparin subcutaneously per day safely and effectively reduces the risk of venous thromboembolism in patients with acute medical illnesses.  (+info)

Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. (5/358)

BACKGROUND: Low-molecular-weight heparins are attractive alternatives to unfractionated heparin (UFH) for management of unstable angina/non-Q-wave myocardial infarction (UA/NQMI). METHODS AND RESULTS: Patients (n=3910) with UA/NQMI were randomized to intravenous UFH for >/=3 days followed by subcutaneous placebo injections or uninterrupted antithrombin therapy with enoxaparin during both the acute phase (initial 30 mg intravenous bolus followed by injections of 1.0 mg/kg every 12 hours) and outpatient phase (injections every 12 hours of 40 mg for patients weighing <65 kg and 60 mg for those weighing >/=65 kg). The primary end point (death, myocardial infarction, or urgent revascularization) occurred by 8 days in 14.5% of patients in the UFH group and 12.4% of patients in the enoxaparin group (OR 0.83; 95% CI 0.69 to 1.00; P=0. 048) and by 43 days in 19.7% of the UFH group and 17.3% of the enoxaparin group (OR 0.85; 95% CI 0.72 to 1.00; P=0.048). During the first 72 hours and also throughout the entire initial hospitalization, there was no difference in the rate of major hemorrhage in the treatment groups. During the outpatient phase, major hemorrhage occurred in 1.5% of the group treated with placebo and 2.9% of the group treated with enoxaparin (P=0.021). CONCLUSIONS: Enoxaparin is superior to UFH for reducing a composite of death and serious cardiac ischemic events during the acute management of UA/NQMI patients without causing a significant increase in the rate of major hemorrhage. No further relative decrease in events occurred with outpatient enoxaparin treatment, but there was an increase in the rate of major hemorrhage.  (+info)

Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. (6/358)

BACKGROUND: Two phase III trials of enoxaparin for unstable angina/non-Q-wave myocardial infarction have shown it to be superior to unfractionated heparin for preventing a composite of death and cardiac ischemic events. A prospectively planned meta-analysis was performed to provide a more precise estimate of the effects of enoxaparin on multiple end points. METHODS AND RESULTS: Event rates for death, the composite end points of death/nonfatal myocardial infarction and death/nonfatal myocardial infarction/urgent revascularization, and major hemorrhage were extracted from the TIMI 11B and ESSENCE databases. Treatment effects at days 2, 8, 14, and 43 were expressed as the OR (and 95% CI) for enoxaparin versus unfractionated heparin. All heterogeneity tests for efficacy end points were negative, which suggests comparability of the findings in TIMI 11B and ESSENCE. Enoxaparin was associated with a 20% reduction in death and serious cardiac ischemic events that appeared within the first few days of treatment, and this benefit was sustained through 43 days. Enoxaparin's treatment benefit was not associated with an increase in major hemorrhage during the acute phase of therapy, but there was an increase in the rate of minor hemorrhage. CONCLUSIONS: The accumulated evidence, coupled with the simplicity of subcutaneous administration and elimination of the need for anticoagulation monitoring, indicates that enoxaparin should be considered as a replacement for unfractionated heparin as the antithrombin for the acute phase of management of patients with high-risk unstable angina/non-Q-wave myocardial infarction.  (+info)

Comparison of low-molecular-weight heparin (enoxaparin sodium) and standard unfractionated heparin for haemodialysis anticoagulation. (7/358)

BACKGROUND: Low-molecular-weight heparin (LMWH) has been suggested as providing safe, efficient, convenient and possibly more cost-effective anticoagulation for haemodialysis (HD) than unfractionated heparin, with fewer side-effects and possible benefits on uraemic dyslipidaemia. METHODS: In this prospective, randomized, cross-over study we compared the safety, clinical efficacy and cost effectiveness of Clexane (enoxaparin sodium; Rhone-Poulenc Rorer) with unfractionated heparin in 36 chronic HD patients. They were randomly assigned to either Clexane (1 mg/kg body weight, equivalent to 100 IU) or standard heparin, and followed prospectively for 12 weeks (36 dialyses) before crossing over to the alternate therapy for a further 12 weeks. Heparin anticoagulation was monitored using activated coagulation times. RESULTS: Dialysis with Clexane resulted in less frequent minor fibrin/clot formation in the dialyser and lines than with heparin (P<0.001), but was accompanied by increased frequency of minor haemorrhage between dialyses (P<0.001). Clexane dose reduction (to a mean of 0.69 mg/kg) eliminated excess minor haemorrhage without increasing clotting frequencies. Mean vascular compression times were similar in both groups. Over 24 weeks, no changes in standard serum lipid profiles were observed. CONCLUSIONS: This study suggests that a single-dose protocol of Clexane is an effective and very convenient alternative to sodium heparin, but currently direct costs are about 16% more. We recommend an initial dose of 0.70 mg/kg.  (+info)

Intraoperative heparin in addition to postoperative low-molecular-weight heparin for thromboprophylaxis in total knee replacement. (8/358)

The administration of heparin during operation has been reported to enhance the efficacy of thromboprophylaxis in patients undergoing total hip replacement. We have performed a small pilot study in which intraoperative doses of heparin were given in addition to the usual postoperative thromboprophylaxis with enoxaparin in 32 patients undergoing total knee replacement. The primary endpoint was deep-vein thrombosis (DVT) as demonstrated by bilateral venography on 6 +/- 2 days after operation. Sixteen patients developed DVT; in two the thrombosis was proximal as well as distal and in one the occurrence was bilateral. There was one major haemorrhage. These results are similar to those obtained with the use of postoperative thromboprophylaxis with enoxaparin alone. They do not provide support for the initiation of a larger randomised trial of this approach to management.  (+info)

enoxaparin sodium hs code manufacturers and enoxaparin sodium hs code suppliers Directory - Find enoxaparin sodium hs code Manufacturers, Exporters and enoxaparin sodium hs code suppliers on ECVERY.com
TY - JOUR. T1 - Analysis of Enoxaparin Dose Titration at a Large, Tertiary Teaching Facility. AU - Freer, J. Matt. AU - Green, Melissa S.. AU - Iuppa, Jennifer A.. AU - Deal, Eli N.. AU - Thoelke, Mark S.. PY - 2015/11/1. Y1 - 2015/11/1. N2 - Therapeutic drug monitoring of enoxaparin with antifactor Xa levels (AXALs) is recommended in some populations; however, the approach to dose titration is poorly described. Our study at a large, tertiary teaching facility examined the dose response to titration of enoxaparin based on AXAL. Patients from 2008 to 2012 receiving enoxaparin were included, provided 2 or more steady state AXAL were obtained within 30 days and that the enoxaparin was prescribed for treatment rather than prophylaxis. The primary outcome was the percentage of dose change required to obtain goal range AXAL following dose titration. Eighty-seven patients were available for analysis with the following key characteristics: renal dysfunction during treatment 72%, obesity 8%, and solid ...
Abdominal Surgery: In patients undergoing abdominal surgery who are at risk for thromboembolic complications, the recommended dose of enoxaparin sodium injection is 40 mg once a day administered by SC injection with the initial dose given 2 hours prior to surgery. The usual duration of administration is 7 to 10 days; up to 12 days administration has been administered in clinical trials.. Hip or Knee Replacement Surgery: In patients undergoing hip or knee replacement surgery, the recommended dose of enoxaparin sodium injection is 30 mg every 12 hours administered by SC injection. Provided that hemostasis has been established, the initial dose should be given 12 to 24 hours after surgery. For hip replacement surgery, a dose of 40 mg once a day SC, given initially 12 (±3) hours prior to surgery, may be considered. Following the initial phase of thromboprophylaxis in hip replacement surgery patients, it is recommended that continued prophylaxis with enoxaparin sodium injection 40 mg once a day be ...
Cases of epidural or spinal hemorrhage and subsequent hematomas have been reported with the use of enoxaparin sodium injection and epidural or spinal anesthesia/analgesia or spinal puncture procedures, resulting in long-term or permanent paralysis. The risk of these events is higher with the use of postoperative indwelling epidural catheters, with the concomitant use of additional drugs affecting hemostasis such as NSAIDs, with traumatic or repeated epidural or spinal puncture, or in patients with a history of spinal surgery or spinal deformity [see Boxed Warning, Adverse Reactions (6.2) and Drug Interactions (7)]. To reduce the potential risk of bleeding associated with the concurrent use of enoxaparin sodium and epidural or spinal anesthesia/analgesia or spinal puncture, consider the pharmacokinetic profile of enoxaparin [see Clinical Pharmacology (12.3)]. Placement or removal of an epidural catheter or lumbar puncture is best performed when the anticoagulant effect of enoxaparin is low; ...
Bioequivalence of a biosimilar enoxaparin sodium to ClexaneReg after single 100 mg subcutaneous dose: results of a randomized, double-blind, crossover study in healthy volunteers Javier Martínez González, Mayte Monreal, Ignacio Ayani Almagia, Jordi Llaudó Garín, Lourdes Ochoa Díaz de Monasterioguren, Ibón Gutierro Adúriz R&D Department, Laboratorios Farmacéuticos Rovi S.A., Madrid, Spain Purpose: To demonstrate the pharmacokinetic/pharmacodynamic (PK/PD) equivalence of a biosimilar enoxaparin to the reference drug, and to assess its safety and tolerability in healthy volunteers. Patients and methods: A randomized, double-blind, crossover, 2-sequence, single-dose study was conducted in healthy volunteers of both sexes. Participants were sequentially and randomly administered single subcutaneous injections of enoxaparin 100 mg manufactured by Rovi (test; Madrid, Spain) and Clexane® (enoxaparin 100 mg manufactured by Sanofi, reference) separated by a 1-week washout period. The primary PK/PD
This study demonstrates that UA/NSTEMI patients who would have been excluded from the randomized enoxaparin trials can be safely treated with a weight-adjusted regimen of subcutaneous enoxaparin, as long as particular attention is paid to age and renal function to further adjust the dosing regimen. The EP population represents a high-risk group of patients who had a fourfold increase in death or MI at 30 days. Hypertension and the use of GP IIb/IIIa inhibitors were the only predictors of bleeding found in our study population.. There is strong evidence that antithrombin therapy is beneficial in UA/NSTEMI patients and that subcutaneous enoxaparin is superior to UH in this setting (1-3). However, this demonstration has been obtained in selected populations, and it is not known whether these results can be applied to all comers who present with UA/NSTEMI, including those who would have been excluded from these randomized trials. Furthermore, the safety of enoxaparin in a population at a high risk ...
Important Safety Information Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins (LMWH) or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture, resulting in long-term or permanent paralysis. Enoxaparin Sodium Injection, USP is contraindicated in patients with active major bleeding; thrombocytopenia with a positive in vitro test for anti-platelet antibody in the presence of enoxaparin sodium; or known hypersensitivity to enoxaparin sodium, heparin, or pork products. Serious adverse reactions reported with enoxaparin sodium injection include increased risk of hemorrhage and thrombocytopenia. Enoxaparin Sodium Injection, USP should be used with extreme caution in conditions with increased risk of hemorrhage, or in patients treated concomitantly with platelet inhibitors. Major hemorrhages including retroperitoneal and intracranial bleeding have been reported with enoxaparin sodium injection. Some of these cases ...
Wholesale Trader of Pharmaceutical Injection - Enoxaparin Sodium Injection, Imipenem And Cilastatin Injection, 40 mg Enoxaparin Sodium Injection and Vasopressin Injection offered by Shom Health Care, Mumbai, Maharashtra.
NDC Code 63323-605-94 is assigned to a package of 10 cello pack in 1 carton > 1 syringe in 1 cello pack (63323-605-04) > 1 ml in 1 syringe of Enoxaparin Sodium, a human prescription drug labeled by Fresenius Kabi Usa, Llc.
Background- The combination of a single-bolus fibrinolytic and a low-molecular-weight heparin may facilitate prehospital reperfusion and further improve clinical outcome in patients with ST-elevation myocardial infarction.. Methods and Results- In the prehospital setting, 1639 patients with ST-elevation myocardial infarction were randomly assigned to treatment with tenecteplase and either (1) intravenous bolus of 30 mg enoxaparin (ENOX) followed by 1 mg/kg subcutaneously BID for a maximum of 7 days or (2) weight-adjusted unfractionated heparin (UFH) for 48 hours. The median treatment delay was 115 minutes after symptom onset (53% within 2 hours). ENOX tended to reduce the composite of 30-day mortality or in-hospital reinfarction, or in-hospital refractory ischemia to 14.2% versus 17.4% for UFH (P=0.080), although there was no difference for this composite end point plus in-hospital intracranial hemorrhage or major bleeding (18.3% versus 20.3%, P=0.30). Correspondingly, there were reductions in ...
WHITE PHARMACEUTICALS - Exporter, Importer, Distributor, Supplier, Trading Company of Enoxaparin - Low Molecular Weight Heparin based in New Delhi, India
A direct comparison of intravenous enoxaparin with unfractionated heparin in primary percutaneous coronary intervention (from the ATOLL Trial) Academic Article ...
TY - JOUR. T1 - High dose low-molecular-weight heparin (enoxaparin) for the treatment of recurrent thromboembolism in pregnancy. AU - Jha, R.. AU - Lindow, S. W.. AU - Masson, E. A.. AU - Atkin, Stephen. PY - 1997. Y1 - 1997. UR - http://www.scopus.com/inward/record.url?scp=0030941581&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0030941581&partnerID=8YFLogxK. M3 - Article. C2 - 15511813. AN - SCOPUS:0030941581. VL - 17. SP - 168. JO - Journal of Obstetrics and Gynaecology. JF - Journal of Obstetrics and Gynaecology. SN - 0144-3615. IS - 2. ER - ...
Background and Introduction:. Venous thromboembolism (VTE) is a significant cause of morbidity and mortality in hospitalized patients. It is a well-known complication in patients after major surgery or trauma. More recently, medically ill patients have been identified as another high risk group with up to 15% of patients experiencing VTE in the absence of prophylaxis. 1 Several studies have found the use of enoxaparin, dalteparin, and fondaparinux to be safe and effective in reducing risk of VTE by 45% to 63% in medically ill patients. 1-3 Additionally, enoxaparin has been found to be at least as safe and effective as unfractionated heparin for VTE prophylaxis. 4 Enoxaparin 40 mg once daily has been shown to be a safe and effective prophylactic therapy in hospitalized patients. 1. In thromboprophylaxis studies, including those investigating enoxaparin 40 mg once daily, morbidly obese patients (greater than or equal to 35 kg/m2) have been grossly under-enrolled. This is problematic for several ...
Get a FREE Enoxaparin Injection coupon and drug savings card and save up to 80% or more on Enoxaparin Injection. Use your Enoxaparin Injection coupon at over 60,000 USA pharmacies.
Drug utilization evaluation (DUE) is an effective program to identify variability in drug use and to support interventions that will improve patient outcomes. The appropriate use of enoxaparin, a low molecular weight heparin (LMWH), which is widely used as curative or preventive treatment of thromboembolic disorders was assessed in the study. A prospective DUE was carried out at Masih Daneshvari teaching hospital. Criteria for the appropriate use of enoxaparin was used to evaluate prescription and administration patterns in this hospital. Enoxaparin utilization of 147 inpatients was reviewed. A total of 944 variables (70.92%) in the regimen, among all subjects, were rated as appropriate and 382 (28.70%) were rated as inappropriate for the conditions diagnosed. The results of this study showed that inappropriate dosing, administration and prescribing of enoxaparin is rather common in masih hospital. Educational programs and implementation of protocols may be needed in the teaching hospitals to control
Primary Aim: To address whether, among pediatric patients with congenital heart defects (CHD) recovering from cardiovascular surgery and diagnosed with an asymptomatic venous TE, the use of enoxaparin results in a net therapeutic benefit. We hypothesize that enoxaparin dosed as per age-appropriate algorithms is associated with an increased rate of clot resolution and decreased rate of clot progression/long-term complications in children with CHD and asymptomatic venous TE. Benefits from clot resolution will outweigh the risks associated with the use of enoxaparin resulting in a net therapeutic benefit in favour of enoxaparin use in this context.. Secondary aims of this study are to:. ...
Enoxaparin and Fondaparinux are potential anticoagulants which are used peri-operatively in the management of patients with Acute Coronary Syndrome (ACS). We aimed to compare the adverse clinical outcomes which are associated with the use of these anticoagulants in patients who were treated for ACS. Online databases (PubMed/Medline, EMBASE, Cochrane library) were searched for studies which compared differences in clinical outcomes observed with the use of enoxaparin and fondaparinux in patients who were treated peri-operatively for ACS. Statistical analysis was carried out by Revman 5.3 software with odds ratio (OR) and 95% confidence intervals (CI) as the analytical parameters. Seven studies with a total number of 9618 patients (mainly composed of non-ST elevated myocardial infarction/NSTEMI) were included. This analysis showed mortality to be similarly observed between enoxaparin and fondaparinux with OR: 1.05, 95% CI: 0.67-1.63; P = 0.84. Myocardial infarction (MI) and stroke were also not
Über die optimalen Strategien der Antikoagulation während und nach einem gefäßchirurgischen Eingriff wird in Expertenkreisen derzeit noch diskutiert und beraten. Es bestehen zum jetzigen Zeitpunkt noch keine Dosierungsempfehlungen für niedermolekulare Heparine im perioperativen Management bei Rekonstruktionen der arteriellen Gefäßstrombahn. Die Therapie variiert je nach Art der Operation, der Art des Implantates sowie der klinischen Gesamtsituation des Patienten. Aus den erheblichen Unterschieden in der Anwendung der perioperativen Thromboseprophylaxe bei arteriellen gefäßchirurgischen Operationen ist abzuleiten, dass dringend ein Bedarf an einer optimalen Dosisfindung besteht. Die Sicherheit und Effektivität von Enoxaparin in der perioperativen Anwendung zur Thromboseprophylaxe bei arteriellen gefäßchirurgischen Interventionen ist bereits in anderen Studien gezeigt worden. Dies führte dazu, eine Studie zur Findung der optimalen Dosierung von Enoxaparin im perioperativen Management ...
TY - JOUR. T1 - Prophylaxis with enoxaparin for prevention of venous thromboembolism after lung transplantation: a retrospective study. AU - Sáez-Giménez, Berta. AU - Berastegui, Cristina. AU - Sintes, Helena. AU - Perez-Miranda, Javier. AU - Figueredo, Ana. AU - López Meseguer, Manuel. AU - Monforte, Víctor. AU - Bravo, Carlos. AU - Santamaría, Amparo. AU - Ramon, Maria Antonia. AU - Gómez-Ollés, Susana. AU - Roman, Antonio. PY - 2017/12/1. Y1 - 2017/12/1. N2 - © 2017 Steunstichting ESOT Venous thromboembolism (VTE) is a frequent complication after solid organ transplantation (SOT) and, specifically, after lung transplantation (LT). The objectives of this study were to evaluate prophylaxis with enoxaparin and to describe risk factors for VTE after LT. We retrospectively reviewed the clinical records of 333 patients who underwent LT in our institution between 2009 and 2014. We compared two consecutive cohorts: one that received enoxaparin only during post-transplant hospital admissions ...
In worldwide, the mortality rate of acute myocardial infarction (AMI) raises year by year. Although the applications of percutaneous coronary intervention (PCI) and anticoagulants effectively reduce the mortality of patients with acute coronary syndrome (ACS), but also increase the incidence of bleeding. Therefore, drugs with stable anticoagulant effects are urgently required. We enrolled 894 patients with acute coronary syndrome who underwent percutaneous coronary intervention in Shenyang Northern Hospital from February 2010 to May 2012; 430 patients were included in the fondaparinux group (2.5 mg/d), and 464 were included in the enoxaparin group (1 mg/kg twice daily). Fondaparinux and enoxaparin were applied for 3-7 days. All patients were treated with tirofiban (10 μg/kg for 3 min initially and 0.15 μg/(kg · min) for 1 to 3 days thereafter). The primary efficacy endpoint was the incidence of a major adverse cerebrovascular or cardiovascular event. The primary safety endpoint was bleeding within 30
The authors found that, compared with enoxaparin, rivaroxaban was associated with a lower risk of VTE (relative risk 0.48, 95% confidence interval 0.31 to 0.75; P- value= 0.001), however, neither dabigatran (0.71, 0.23 to 2.12; P= 0.54) nor apixaban (0.82, 0.41 to 1.64; P= 0.57) reduced the risk of symptomatic VTE. Compared with enoxaparin, the relative risk of clinically relevant bleeding was higher with rivaroxaban (1.25, 95% CI 1.05 to 1.49; P= 0.01), similar with dabigatran (1.12, 0.94 to 1.35; P=0.21), and lower with apixaban (0.82, 0.69 to 0.98; P= 0.03). The treatments did not differ on the net clinical endpoint in direct or indirect comparisons. They concluded that the new anticoagulants did not differ significantly for efficacy and safety from that of enoxaparin; however, they may be associated with a higher bleeding tendency. ...
Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Enoxaparin Sodium (RP54563) 20mg Bid for 14 Days for Prevention of Venous Thromboembolism in Patients With Curative Abdominal Cancer Surgery. Physical Prophylaxis Only Arm [Intermittent Pneumatic Compression (IPC)] Will be Used as an Indicator of Event Rates ...
Enoxaparin Sodium Injection official prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions, pharmacology and more.
CEO Craig Wheeler commented: Royalty revenues from enoxaparin sodium injection in Q3 were disappointing and reflected the market realities of a more competitive multi-player dynamic. We continue ...
Buy Enoxaparin with no prescription online from EU. Purchase Lowest Price International Pharmacy. Order Discount Enoxaparin (Generic) Drug to Europe, France, Germany, Spain, Italy, European Union. Save euro!
Low-molecular-weight heparins (LMWHs) accumulate in patients with impaired renal function. As this accumulation depends on heparin chain length and subsequent reticulo-endothelial/renal elimination, LMWHs might have different pharmacodynamic profiles. The primary objective was to examine if any accumulation effect of two LMWHs, enoxaparin and tinzaparin, occurred after repeated administration of a prophylactic dose over eight days in elderly patients (age |75 years) with creatinine clearance between 20 and 50 ml/min and body weight |65Kg. Patients were openly randomized to two groups (enoxaparin 4,000 IU or tinzaparin 4,500 IU once daily). Anti-Xa was measured on day 1 and day 8. Blood samples were taken at 0, 2, 4, 5, 6, 9, 12, 16 and 24 hours. The primary end point was the accumulation factor calculated as a ratio between the maximal anti-Xa activity on day 1and day 8. Fifty-five patients were included (mean age 87.9 +/- 5.5). The creatinine clearance was 34.7 +/- 11.4 ml/min; the body weight was 52.3
This is a Heparin with low molecular weight There is published evidence of a lack of anti-coagulant activity in the serum of breastfed infants whose mothers were treated with Enoxaparin. The high molecular weight of the so-called standard or non-fragmented Heparin and others called low weight Heparins makes that excretion into breast milk very unlikely. There is scientific proof on the lack of excretion of Dalteparin into breast milk. In addition, Heparin derived drugs are inactivated in the gut and they are not absorbed at all, hence, oral bioavailability is nil. The risk of Heparin-induced Thrombocytopenia and Osteoporosis is lower with low weight Heparin among treated adults.
TIMI 11BESSENCE Comparison of Trials : Dose of Study Rx TIMI 11 B ESSENCE TIMI 11 B ESSENCE IV UFH Bolus 70 U/kg 5000 U Infusion 15 U/kg/h 1000 U/h aPTT (x control) Med Dur. Rx (d) Enoxaparin (Acute) Bolus 30 mg None S.C. Q 12 h (mg/kg) Med Dur. Rx (d) Enoxaparin (Chronic-43 d) 40 mg (65 kg) 60 mg (>65 kg) Antman EM et al, Circulation 1999 Oct 12;100(15):1602-8
...EXCLAIM is the First International Study to Show That ExtendedThrombo...PARIS July 8 2007 /PRNewswire-FirstCall/ --Sanofi-aventisannounced ...Acutely ill medical patients are at high risk of VTE. Thebenefit of t...The objective of EXCLAIM study was to assess the superiority ofenoxap...,New,Study,Shows,That,Extending,Prophylaxis,With,Clexane,/,Lovenox,(enoxaparin,Sodium,Injection),to,5,Weeks,is,More,Effective,Than,10,Days,for,Reducing,the,Risk,of,Venous,Thromboembolism,(VTE),in,Acutely,ill,Medical,Patients,With,Reduced,Mobility,medicine,advanced medical technology,medical laboratory technology,medical device technology,latest medical technology,Health
Enoxaparin is superior to unfractionated heparin after fibrinolysis in acute myocardial infarction: Meta-analysis of ASSENT-3, HART-II, and ENTIRE-TIMI-23 trials
The efficacy and safety of enoxaparin vs unfractionated heparin in prevention of deep vein thrombosis in elective cancer surgery. A double-blind randomized multicentre trial in 1116 patients with veno ...
Massel D. Enoxaparin for 7 days was better than unfractionated heparin for 2 days for reducing death and MI but not bleeding in STEMI. ACP J Club. 2006;145:30. doi: 10.7326/ACPJC-2006-145-2-030. Download citation file:. ...
Enoxaparin sodium. Features information for patients and physicians including tips and instructions, interactions, prescribing information, description of potential uses, and dosing details. ...
Patient on Haemodialysis need Enoxaparin, a drug which is used to prevent blood clotting when the blood goes through the dialysis machine. The manufacturers recommendation is to give enoxaparin through the arterial route of the dialysis circuit. About 80% of enoxaparin gets eliminated by dialysis when administered through the arterial route of the circuit. Our hypothesis is that by administering enoxaparin via the venous route we will not lose the 80% of the drug and hence use less amount of enoxaparin. ...
Unpublished data prepared by our department has shown that pregnant women display some resistance to the use of low molecular weight heparins. We would like to compare the use of enoxaparin and tinzaparin in pregnant women who have a previous history of venous thromboembolism, or who have inherited of acquired condition which predisposes them to venous thromboprophylactic doses as recommended by the respective manufacturers and monitoring the effects by using anti factor Xa assays and thromboelastography. ...
Enoxaparin is a low-molecular-weight heparin (LMWH) that differs substantially from unfractionated heparin (UFH) in its pharmacodynamic and pharmacokinetic properties. Some of the pharmacodynamic...
Background: Non ST-segment elevation myocardial infarction (NSTEMI) has been known to have comorbidities, such as type 2 diabetes mellitus (T2DM). Diabetic increases the risk of cardiovascular event by 2 - 4 times compared with non-diabetic (NDM) patients. In diabetic patients, there are haemostasis disturbances, such as platelet hypereactivity, hypercoagulation, and decrease of fibrinolysis. This condition may lead to decrease of anticoagulant effect and become higher risk of stent thrombosis, target vessel revascularization, reinfarction, and major cardiovascular event (MACE). This study aims to assess the effect of anticoagulant in terms of bleeding and MACE in NSTEMI with T2DM. Methode: A total of 67 patients diagnosed with IMA-NEST and T2DM who hospitalized in Adam Malik general hospital since January 2018 until October 2018 were recruited in this ambispective study. The patients were divided into 2 groups, enoxaparin and fondaparinux. In hospital bleeding and MACE were observed, including ...
There are well-known limitations to any use of results from separate clinical trial programs to estimate relative efficacy of different drugs. Nevertheless, for rivaroxaban and dabigatran, in these large studies the demographics of study populations appear similar, as were study inclusion and exclusion criteria, so results should be broadly comparable - provided comparisons are of relative and not absolute outcome rates.. With that proviso, the results with rivaroxaban appear more impressive, since 10 mg once daily started 6-8 hours after surgery was superior to enoxaparin 40 mg once daily for several outcomes with a similar risk of bleeding. The efficacy and bleeding risk of dabigatran etexilate 220 mg once daily was similar to enoxaparin 40 mg once daily. While dabigatran etexilate 150 mg once daily was formally non-inferior to enoxaparin, the total rates of venous thromboembolism were consistently higher than with 220 mg once daily or with enoxaparin 40 mg once daily and bleeding rates were ...
DURHAM, N.C. - Three studies led by Duke Clinical Research Institute (DCRI) cardiologists have shown that the ease and convenience of a newer formulation of the blood-thinner heparin, called enoxaparin, appear to make it the drug of choice for treating patients with suspected heart attacks. Enoxaparin has comparable and sometimes better mortality outcomes than the older formulation, found the researchers.. However, they said, the studies results did not provide clear-cut evidence of superiority of enoxaparin. Additionally, they stressed that based on their results, patients should not be switched from one formulation to the other during the course of treatment.. Unfractionated heparin is given intravenously and requires continuous monitoring to ensure proper blood levels of the drug. Enoxaparin is given by subcutaneous injection in fixed dosages and does not require blood level monitoring.. The results were published in three reports in the July 7, 2004, issue of the Journal of the American ...
Morrison and colleagues review on the medical consultants role in the care of patients with hip fracture (1) was very interesting and thorough. Despite this and many other articles, however, prophylactic management of deep venous thrombosis is far from clear. Weight-adjusted low-molecular-weight heparin therapy is probably not necessary, and fixed-dose low-molecular-weight heparin may become standard of practice, as reinforced by Haentjens (2). Although Morrison and associates suggested starting low-molecular-weight heparin before surgery, at present data are limited. Studies are unequivocal, however, about postoperative therapy with enoxaparin sodium (3). Noble and colleagues reported that enoxaparin, 40 mg once daily, started before surgery was more effective than unfractionated heparin, but further studies are needed ...
Enoxaparin; Major bleeding; Kidney dysfunction; GFR; Meta analysis; Bleeding; MOLECULAR-WEIGHT HEPARIN; UNSTABLE ANGINA PATIENTS; ACUTE-CORONARY-SYNDROME; RENAL-FUNCTION; UNFRACTIONATED HEPARIN; PHARMACOKINETICS; IMPAIRMENT; PHARMACODYNAMICS; ANTICOAGULATION; ...
These data suggest that the treatment benefit of enoxaparin may be through preventing reocclusion of culprit lesions in patients who achieve initial reperfusion with thrombolysis. The data support the use of anticoagulation with enoxaparin for patients without contraindications who receive fibrinolytic therapy. Moreover, the data reinforce the monitoring for STRes after fibrinolysis, as the degree of STRes has predictive value. Failure to achieve STRes should prompt referral for revascularization. Conversely, patients who achieve early complete STRes and are treated with enoxaparin and antiplatelet therapy can be safely monitored until they are electively referred for catheterization or risk-stratified for medical management, as they are at very low risk for recurrent ischemic complications.. ...
If aggregates of the sticky amyloid-β can contribute to the pathology of Alzheimers disease (AD), then maybe unsticking them will help reverse the process. Far-fetched? Luigi Bergamaschini and colleagues have already demonstrated that anticoagulants such as heparin can attenuate the inflammatory and toxic effects of Aβ in vitro (see Bergamaschini et al., 2002). Now, in the April 28 Journal of Neuroscience, they extend this observation to an in-vivo model of AD.. Bergamaschini, from the University of Milan, together with Maria Grazia De Simoni, from the Mario Negri Institute for Pharmacological Research, also in Milan, administered the low molecular weight heparin enoxaparin to APP23 mice, which overexpress human amyloid precursor protein. The authors chose enoxaparin because of the high risk of bleeding associated with unfractionated heparin. In addition, heparins are known to bind to a short amino acid stretch in amyloid β (residues 13-16).. Bergamaschini treated 12-month-old APP23 mice ...
PubMed journal article: Apixaban vs Enoxaparin for Postoperative Prophylaxis: Safety of an Oral Alternative for the Prevention of Venous Thromboembolism. Download Prime PubMed App to iPhone, iPad, or Android
The prices of elevation of the alanine aminotransferase and total bilirubin amounts to at least 3 times the higher limit of the standard range didnt differ between your two groups. Discussion The primary efficacy final result, a composite of venous thromboembolism and death related to venous thromboembolism, happened in 2.71 percent of the individuals randomly assigned to apixaban and in 3.06 percent of these assigned to enoxaparin . However, there is an almost immediate upsurge in the risk of occasions when enoxaparin was stopped. Following the parenteral-treatment period, the primary efficacy final result occurred in 31 sufferers in the enoxaparin group but in only 18 sufferers receiving expanded treatment with apixaban .Related StoriesPeople confused about antibiotic resistance, displays WHO surveyStudy links antibiotic make use of during childhood to excess weight gainPhysicians keep severe acne individuals on ineffective antibiotics for too much time before prescribing more potent drugAHRQ ...
article{62467ba8-5393-440f-b737-11cd1101dfa8, abstract = {Background: Abdominal surgery for cancer carries a high risk of venous thromboembolism, but the optimal duration of postoperative thromboprophylaxis is unknown. Methods: We conducted a double-blind, multicenter trial in which patients undergoing planned curative open surgery for abdominal or pelvic cancer received enoxaparin (40 mg subcutaneously) daily for 6 to 10 days and were then randomly assigned to receive either enoxaparin or placebo for another 21 days. Bilateral venography was performed between days 25 and 31, or sooner if symptoms of venous thromboembolism occurred. The primary end point with respect to efficacy was the incidence of venous thromboembolism between days 25 and 31. The primary safety end point was bleeding during the three-week period after randomization. The patients were followed for three months. Results: The intention-to-treat analysis of efficacy included 332 patients. The rates of venous thromboembolism at ...
Biocad is developing a biosimilar version of enoxaparin sodium (BCD 080), a low molecular weight heparin, for the treatment and prevention of venous
Influence of Direct Thrombin Inhibitor and Low Molecular Weight Heparin on Platelet Function in Patients with Coronary Artery Disease: A Prospective Interventional Trial
Seven studies with a total number of 9618 patients (mainly composed of non-ST elevated myocardial infarction/NSTEMI) were included. This analysis showed mortality to be similarly observed between enoxaparin and fondaparinux with OR: 1.05, 95% CI: 0.67-1.63; P = 0.84. Myocardial infarction (MI) and stroke were also not significantly different throughout different follow up periods. However, minor, major and total bleeding were significantly lower with fondaparinux (OR: 0.40, 95% CI: 0.27-0.58; P = 0.00001), (OR: 0.46, 95% CI: 0.32-0.66; P = 0.0001) and (OR: 0.47, 95% CI: 0.37-0.60; P = 0.00001) respectively during the 10-day follow up period. Even during a follow up period of 30 days or a midterm follow up, major and minor bleeding still significantly favored fondaparinux in comparison to enoxaparin. ...
9 December 2019 - The US Food and Drug Administration (FDA) has granted approval to Meitheal Pharmaceuticals, a fully integrated generic injectables company, for its Enoxaparin Sodium Injection, USP, the generic equivalent of Lovenox, it was reported on Friday.. The company licenses Enoxaparin Sodium Injection exclusively through its collaboration with Nanjing King-friend (NKF) Biochemical Pharmaceutical Co Ltd, its majority shareholder. Enoxaparin Sodium Injection, USP is a low molecular weight heparin (LMWH) indicated for: Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness.. Tom Shea, chief executive officer of Meitheal Pharmaceuticals, said, We are excited to be making such progress in our mission to bridge major gaps in healthcare by guaranteeing quality, affordable generic injectables that address an array of patient needs by offering a vertically ...
TY - JOUR. T1 - P-selectin/ PSGL-1 Inhibitors versus enoxaparin in the resolution of venous thrombosis. T2 - A meta-analysis. AU - Ramacciotti, Eduardo. AU - Myers, Daniel D.. AU - Wrobleski, Shirley K.. AU - Deatrick, K. Barry. AU - Londy, Frank J.. AU - Rectenwald, John E.. AU - Henke, Peter K.. AU - Schaub, Robert G.. AU - Wakefield, Thomas W.. PY - 2010/4/1. Y1 - 2010/4/1. N2 - Background: P-selectin antagonism has been shown to decrease thrombogenesis and inflammation in animal models of deep venous thrombosis (DVT). Objective: To determine the effectiveness of P-selectin inhibitors versus saline and enoxaparin in venous thrombus resolution in nonhuman primate models of venous thrombosis. Methods: Studies reporting vein re-opening, inflammation expressed as Gadolinium enhancement and coagulation parameters were searched in the literature and pooled into a meta-analysis using an inverse variance with random effects. Results: Five studies were identified comparing P-selectin/ PSGL-1 ...
Background Two phase 3 trials compared 28-35 days of treatment with oral dabigatran 220 mg or 150 mg (RE-NOVATE) or 220 mg (RE-NOVATE II) once daily with subcutaneous enoxaparin 40 mg once daily for...
TY - JOUR. T1 - Enoxaparin ameliorates post-traumatic brain injury edema and neurologic recovery, reducing cerebral leukocyte endothelial interactions and vessel permeability in vivo. AU - Li, Shengjie. AU - Marks, Joshua A.. AU - Eisenstadt, Rachel. AU - Kumasaka, Kenichiro. AU - Samadi, Davoud. AU - Johnson, Victoria E.. AU - Holena, Daniel N.. AU - Allen, Steven R.. AU - Browne, Kevin D.. AU - Smith, Douglas H.. AU - Pascual, Jose L.. PY - 2015/7/3. Y1 - 2015/7/3. N2 - BACKGROUND: Traumatic brain injury (TBI) confers a high risk of venous thrombosis, but early prevention with heparinoids is often withheld, fearing cerebral hematoma expansion. Yet, studies have shown heparinoids not only to be safe but also to limit brain edema and contusion size after TBI. Human TBI data also suggest faster radiologic and clinical neurologic recovery with earlier heparinoid administration. We hypothesized that enoxaparin (ENX) after TBI blunts in vivo leukocyte (LEU) mobilization to injured brain and cerebral ...
Enoxaparin : medicine prices in Pakistan at WhatPriceDrugs.com. List of Medication containing Enoxaparin. Get information about generic, dosage forms, pack sizes and latest price.
Acronym using Enoxaparin. Acronym including the word Enoxaparin Acronyms with ENOXAPARINFurther acronym search. Find the acronyms that include a word!
There are conflicting results as regards the impact of low molecular weight heparin (LMWH) on bleeding and mortality in elderly patients.. Aim: to compare in-hospital mortality in pts with AMI according to type of heparin used.. Methods: FAST-MI is a nationwide French registry carried out over a one-month period in the fall 2005, including consecutive pts with AMI admitted to CCUs =75 years and had received heparin therapy. Of those, 301 received unfractionated heparin (UFH) only, 398 LMWH only and 185 both UFH and LMWH. UFH only patients were slightly older (83 vs 82 years, p,0.01) and patients on LMWH only more often had NSTEMI: 65% vs 55% (UFH) and 50% (UFH+LMWH), p,0.01). Major bleeding was found in 6.3% (UFH), 2.3% (LMWH) and 2.7% (UFH+LMWH) (p,0.02). Blood transfusion was used in 10% (UFH), 4.8% (LMWH) and 4.3% (UFH+LMWH) (p,0.01). After x-variate adjustment, compared with UFH only, the need for transfusion was significantly lower (p,0.03) for LMWH OR=0.45 (95%CI: 0.25-0.85) and for ...
Fondaparinux is Similar to Enoxaparin in Preventing Ischemic Events Among Patients with Acute Coronary Syndromes but Causes Less Bleeding
The primary outcome in this Lancet study was the composite of asymptomatic and symptomatic deep vein thrombosis (DVT), non-fatal pulmonary embolism (PE), and all-cause death during treatment. The primary outcome was reported in 15% of apixaban patients and 24% of enoxaparin patients (relative risk 0·62), absolute risk reduction 9·3 ...
By Kurt R. Karst -. Earlier today, FDA issued its long-awaited response (45 pages) to a February 2003 citizen petition submitted to the Agency on behalf of Aventis Pharmaceuticals, Inc. (Aventis) concerning the approval of generic versions of the companys anti-coagulant drug LOVENOX (enoxaparin sodium injection). FDA approved LOVENOX in March 1993 under NDA No. 20-164.. Aventis requested that FDA not approve an ANDA for generic LOVENOX unless certain conditions are met - specifically, (1) until enoxaparin has been fully characterized . . . unless the manufacturing process used to create the generic drug product is determined to be equivalent to Aventiss manufacturing process for enoxaparin or the application is supported by proof of equivalent safety and effectiveness demonstrated through clinical trials; and (2) unless the generic product contains a 1,6 anhydro ring structure at the reducing ends of between 15 percent and 25 percent of its poly(oligo)saccharide chains. FDA granted ...
Methods: Included were 30 RAS patients consecutively referred to our centers without any systemic diseases. The ulcers were examined in terms of size and number. Recurrence intervals were recorded by the patients. 1 U/0.002 mL enoxaparin was injected subcutaneously (3 mg). Injections were repeated once a week for 8 weeks. The patients were followed monthly for three months. To determine the level of pain, Visual Analogue Scale (VAS) from 0 to 10 was used. The data were statistically analyzed to determine the difference between the number, size, and pain using Wilcoxon test ...
Increasing number of people are being affected with Deep Vein Thrombosis (DVT) which will subsequently increase demand for LMWH. For instance, according to National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention (CDC), February 2018; the precise number of people affected by DVT/PE is unknown, although as many as 900,000 people could be affected (1 to 2 per 1,000) each year in the U.S.. Furthermore, increasing engagement of government healthcare regulatory bodies in developing and delivering effective and cost-effective low molecular weight heparin molecule products in the market is expected to propel the growth of the market. For instance, in 2014, American Society of Health-System Pharmacists (ASHP) issued the policy for safe and effective use of heparin in neonatal patients thereby supporting the development and use of nationally standardized concentrations of heparin when used for maintenance and flush of peripheral and central venous lines ...
Reference may be made to material that has no named author or is prepared by a committee or other group. The following forms are used: 1. Ferguson JJ, Califf RM, Antman EM, et al; SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA.2004;292(1):45-54. 2. Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122(4):564-572. 3. Centers for Disease Control and Prevention (CDC). Prevalence of receiving multiple preventive-care services among adults with Less ...
Reference may be made to material that has no named author or is prepared by a committee or other group. The following forms are used: 1. Ferguson JJ, Califf RM, Antman EM, et al; SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA.2004;292(1):45-54. 2. Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122(4):564-572. 3. Centers for Disease Control and Prevention (CDC). Prevalence of receiving multiple preventive-care services among adults with Less ...
To date, in Australia, there have been no reports of adverse events of the type reported in the United States associated with heparin products. Nevertheless, the TGA has decided to continue to quarantine the affected batches of Clexane so no patients are put at undue risk. An analysis of the clinical significance of the contaminant in Clexane is ongoing.. People having surgery or requiring treatment with heparin products for other reasons at present should be given either Clexane from batches other than those affected by contamination, the alternative low molecular weight heparin known as Fragmin, or an unfractionated heparin product.. Sponsors have advised that supplies of both intravenous heparin and Fragmin available in Australia have been tested and are free of the contaminant affecting these batches of Clexane.. The TGA is working with suppliers of heparin to source additional heparin products. However todays recall in Australia, in addition to the previous recalls of Clexane, together ...
The Hokusai-VTE study was a randomized, multi-centered, double-blinded, double-dummy, non-inferiority trial that evaluated edoxaban 60 mg orally daily compared to warfarin targeted to an INR between 2.0-3.0. All patients received initial parenteral treatment with either enoxaparin or UFH for at least 5 days. The edoxaban group had the drug initiated following the 5 days of initial treatment. Patients continued on edoxaban or warfarin for 3-12 months, at the discretion of the physician. For patients with a creatinine clearance (CrCl) between 30-50 mL/min or weighing ≤ 60 kg, edoxaban was adjusted to 30 mg daily. Patients included were at least 18 years of age and objectively diagnosed with an acute, symptomatic DVT and/or PE. Patients with cancer, treated with heparin or warfarin for more than 48 hours, or with a CrCl < 30 mL/min were excluded. The primary efficacy outcome was the incidence of symptomatic recurrent VTE defined as DVT or non-fatal or fatal PE. The primary safety outcome was the ...
Anti Xa monitoring should only occur when enoxaparin is at steady state, which occurs after about 48 hours (5 half lives). It is not recommended that Xa levels are taken prior to this, as they are unable to be interpreted. Patients receiving enoxaparin for less than 48 hours do not need Anti Xa monitoring. ...
The US$70 million facility was built in the early 90s by Fisons, a British-based pharmaceutical group, and started operations in 1993, manufacturing nedocromil sodium, the active ingredient of Tilade and Tilavist.. In October 1995, Fisons was acquired by Rhone-Poulenc Rorer of France. After the acquisition, the plant was identified as a strategic site and a further US$67 million was invested in 1998 to build a new plant dedicated to the production of Enoxaparin Sodium, and to expand the capacity of the Synthetic Chemical Plant to produce sodium cromoglicate.. In 2000, Rhone-Poulenc merged with Hoechst Group of Germany to form Aventis Pharma. The plant was officially renamed Aventis Pharma Manufacturing Pte Ltd in March, the same year.. From a small team of only 60 staff members in 1991, the number has now grown to more than 130.. Over the years, the plant has been successfully inspected by US FDA, Singapore HSA and France AFSSAPS, and its products are exported to manufacturing sites - primarily ...
The US FDA approval of the first generic version of Sanofi-Aventiss Lovenox (enoxaparin sodium) to Novartis generics arm Sandoz, which uses technology from Momenta Pharmaceuticals, has caused a buzz because the agency has treated the application like a standard but yet complicated ANDA and did not require full clinical studies. ...
There have been a number of recent Datix reports where the wrong dose of LMWH (Enoxaparin, Tinzaparin) has been administered to patients
The Companys primary, non-AGGRASTAT research and development activity is TARDOXAL(TM) for the treatment of Tardive Dyskinesia (TD). The Company is currently awaiting interim results from the Phase II clinical study of TARDOXAL, entitled Tardoxal for the Treatment of Tardive Dyskinesia (TEND-TD). The Companys ability to continue in operation for the foreseeable future remains dependent upon the effective execution of its business development and strategic plans. All amounts referenced herein are in Canadian dollars unless otherwise noted. About AGGRASTAT AGGRASTAT (tirofiban HCl), in combination with heparin, is indicated for the treatment of acute coronary syndrome, including patients who are to be managed medically and those undergoing PTCA or atherectomy. In this setting, AGGRASTAT has been shown to decrease the rate of a combined endpoint of death, new myocardial infarction or refractory ischemia/repeat cardiac procedure. AGGRASTAT has been studied in a setting that included aspirin and ...
This report studies sales (consumption) of Low-Molecular-Weight Heparin in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering
True or False. Low molecular weight heparin (LMWH), which has advantages over unfractionated heparin, has a molecular weight of about 7500 Daltons, which is one half the mean molecular weight of unfractionated heparin. ...
Xarelto (rivaroxaban) is a good medication for preventing blood clots. It doesnt require regular blood tests or changing doses often. However, it can be expensive and theres no way to reverse the medications effects. Lovenox (Enoxaparin) is a good anticoagulant that reduces the risk of death or bleeding, and blood clots are less likely to happen. However, it is only available as an injection which isnt great if youre afraid of needles.
Niedermolekulare Heparine (LMWH) stellen zur Zeit das Mittel der Wahl bei der Thromboseprohylaxe nach chirurgischen Eingriffen in der Orthopädie dar. Bedingt durch unterschiedliche physikalische und chemische Eigenschaften sind LMWH nicht einfach gegeneinander austauschbar. Ein direkter Vergleich niedermolekularer Heparine ist nur unter gleichem Studiendesign im Rahmen einer Evidenz-basierenden Medizin möglich. Die niedermolekularen Heparine Enoxaparin, Certoparin und Dalteparin zeigen keinen signifikanten Unterschied in der Prophylaxe von thrombembolischen Komplikationen bei orthopädischen Hochrisikopatienten. Patientengruppen unter Anwendung von Certoparin weisen einen höheren , jedoch nicht signifikanten Anteil an Komplikationen gegenüber der Gesamtpopulation auf. Daher sollte als Entscheidungskriterium in der Präparateauswahl die offizielle Empfehlung von Präparaten mit 4.000 - 5.000 Anti-Xa-Einheiten beachtet werden. Adipöse Patienten haben ein massiv erhöhtes Risiko (23 fach) im ...
Video articles in JoVE about heparin low molecular weight include Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood.
This randomized phase II trial provides further rationale supporting a compelling explanation for at least part of this resistance, namely very high interstitial concentrations of hyaluronan, he continued. These data also support the use of tumor HA as a potential predictive biomarker for patient selection in the ongoing, global phase III study of PAG versus AG in patients with HA-high PDA.. The HALO-202 trial was conducted in two stages. In stage 1 (March 2013 to April 2014), 146 patients were randomized 1:1 to receive PAG or AG -- but researchers observed an imbalance in thromboembolic events early in the study. The trial was subsequently put on hold and 29 patients receiving PAG continued treatment with AG alone. Seven of these patients went back on PEGPH20 therapy when stage 2 of the trial started (August 2014 to February 2016) with an amended protocol.. In stage 2, patients with thromboembolic events were excluded, enoxaparin (Lovenox) prophylaxis was initiated in both arms, and an ...
Ive been on lovenox/enoxaparin/heparin a few times and really the bruising is inevitable, but like angieb said, its hit or miss. I learned that if I injected really slow on the love handles I got less bruising. If I was more careless or more in the middle of my belly, it was usually worse because there was not as much fat there to absorb the medication. I never had issues with bleeding(not even postpartum), but I think I was extra careful. I avoided razors and only had waxing done the entire time ...
Enoxaparin may also be used for purposes not listed in this medication guide.This is a summary and does NOT have all possible information about this product.This information does not assure that this product is safe, effective, or appropriate for you.If you become pregnant or think you may be pregnant, tell your doctor right away.. However, if your doctor has directed you to take low-dose aspirin for heart attack or stroke prevention (usually at dosages of 81-325 milligrams a day), you should continue taking it unless your doctor instructs you otherwise.If any of these effects persist or worsen, tell your doctor or pharmacist promptly.This medication may also be given by injection into a vein (to prevent clotting of certain hemodialysis catheters) by a health care professional as directed by your doctor ...
Buy Enoxaparinum with no prescription online from EU. Purchase Lowest Price International Pharmacy. Order Discount Enoxaparinum (Enoxaparin) Drug to Europe, France, Germany, Spain, Italy, European Union. Save euro!
Buy generic Clexane Forte online, no prescription, free shipping. No prior prescription needed order discount Clexane Forte (Enoxaparin) from our pharmacy. gen rico, Generisches.
Most sources consider Lovenox (enoxaparin) to be safe to take while nursing. This eMedTV page explores breastfeeding and Lovenox, including the manufacturers recommendations and why this drug is not thought to cause problems for a breastfed child.
Why do lovaxox shots bruise and what is a good way to minimize it? Answered by Dr. Michael Dugan: Lovenox (enoxaparin): Shots are a long-acting blood thinner. Since the...
The development of sophisticated electronic control systems has led in recent years to many new vehicles entering production that are equipped with various new primary safety features designed to avoid accidents. The assessment of the casualty reduction effectiveness of such features can, however, be very difficult. One reason for this is that when a primary safety feature is fully effective, there is no accident and no data for comparison. This project has attempted to assess the effectiveness of Electronic Stability Control (ESC ...
This morning I had to go in for my repeat Heparin Anti-XA level. Since I was a bit nervous that I was having some brown spotting since I had that broken capillary episode on Friday, I thought that I would have them repeat my beta for the 3rd time so I new that everything was okay. A little before 2pm my clinic called and told me that my 3rd beta was 279 and that my progesterone was still ,40. I immediately started balling my eyes out. I realize that for only being 11dp4dt that 279 is good, however, my last beta on Monday was 165.2 so I only had a 69% increase (63.49 hour doubling time). My first beta was 78.9 so even between the first and second draw I had over a 100% increase. Since an appropriate rise is anything that doubles within 48-72 hours I realize that means I fall within these guidelines, but I have been here before and I dont see this going well. First of all my HCG doubling time slowed from 48 hours to 64 hours and at this point I feel that it should be much quicker. Most women, ...
However, comparison of enoxaparin and tinzaparin shows they are very different from each other with respect to chemical, ... Enoxaparin in Primary and Facilitated Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2010 Feb;3(2):203-12 Dumaine ... Used in the manufacture of enoxaparin (Lovenox and Clexane) Oxidative depolymerisation with Cu2+ and hydrogen peroxide. Used in ... 3 (2011) S100-S104 Jeske, Walter (2013). "Update on the safety and bioequivalence of biosimilars - focus on enoxaparin". Drug ...
"Apixaban better than European enoxaparin regimen for preventing VTE". Retrieved 2011-04-01. "Eliquis (apixaban) [prescribing ...
... is similar to enoxaparin in reducing the risk of ischemic events at nine days, but it substantially reduces major ... "NEJM -- Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes". Retrieved 2009-01-23. Peters RJ, Joyner C, ...
Commonly used low molecular weight heparins are enoxaparin, dalteparin, nadroparin and tinzaparin. In HIT, the platelet count ...
Low-dose low molecular weight heparin (e.g. enoxaparin) may be used. For life-threatening complications, the platelet count can ...
The heparin-like drug known as fondaparinux appears to be better than enoxaparin. A blood test is generally performed for ... Bundhun, PK; Shaik, M; Yuan, J (8 May 2017). "Choosing between Enoxaparin and Fondaparinux for the management of patients with ...
1998). "Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous ... 2002). "Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer". N Engl J Med. 346 (13 ... enoxaparin, dalteparin, tinzaparin) are effective in preventing deep vein thromboses and pulmonary emboli in people at risk, ...
Two studies comparing desirudin with enoxaparin (a LMWH) or unfractionated heparin have been performed. In both studies ...
Similar issues are likely associated with the use of enoxaparin (a LMWH) in these high-risk individuals. Prevention of DVT and ...
Its products include Enoxaparin Sodium Injection, Cortrosyn, Amphadase, Emergency Syringes in Luer-Jet, Lidocaine, Naloxone, ...
Usually, warfarin is avoided in the first trimester, and a low molecular weight heparin such as enoxaparin is substituted. With ...
B01AB05 Enoxaparin. B01AB06 Nadroparin. B01AB07 Parnaparin. B01AB08 Reviparin. B01AB09 Danaparoid. B01AB10 Tinzaparin. B01AB11 ...
In rats anticoagulated by enoxaparin and fondaparinux, andexanet alfa was successful in completely reversing the increased ...
Enoxaparin has 4500 g/mol) These heparins have lower anti-thrombin activity than classical LMWHs and act mainly on factor Xa, ...
"Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic ...
Enoxaparin has 4500 g/mol) These heparins have lower anti-thrombin activity than classical LMWHs and act mainly on factor Xa, ... Clinical trial number NCT00697099 for "Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in ...
... enoxaparin, nadroparin and dalteparin. The ESCAPe-END study". Pharmacology. 78 (3): 136-43. doi:10.1159/000096484. PMID ...
... enoxaparin sodium (INN) enoximone (INN) enoxolone (INN) enpiprazole (INN) enpiroline (INN) enprazepine (INN) Enpresse ...
... enoxaparin, flucloxacillin, insulin, and irrigation of both eyes with saline. Effects of xylazine are also reversed by the ...
... enoxaparin MeSH D09.698.373.400.300.600 --- nadroparin MeSH D09.698.373.400.320 --- heparinoids MeSH D09.698.373.425 --- ...
Under these circumstances, anticoagulation with fondaparinux or enoxaparin is warranted though the benefit for preventing ...
Ferrous salt Ferrous salt/folic acid Folic acid Hydroxocobalamin Erythropoiesis-stimulating agentsα Enoxaparin Heparin sodium ...
Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST- ...
lotucaine (INN) Lotusate lovastatin (INN) Lovenox (Sanofi-Aventis) redirects to enoxaparin loviride (INN) Low-Ogestrel Low-Quel ...
... enoxaparin - ENT - enterostomal therapist - enucleation - enveloped virus - eosinophil - eosinophilia - EP-2101 - ependymal ...
... low molecular weight heparins dalteparin and enoxaparin and of the heparinoid danaparoid on the Rotation thrombelastometry ...
554-558 Superficial Thrombophlebitis Treated By Enoxaparin Study Group/A pilot randomized double-blind comparison of a low- ...
... but this like Enoxaparin was also to a reference product, Genotropin, originally approved as a biologic drug under the FD&C Act ...
Enoxaparin is a FDA pregnancy category B drug which means enoxaparin is not expected to cause harm to an unborn baby when used ... Enoxaparin is in the low molecular weight heparin family of medications. Enoxaparin was first made in 1981 and approved for ... "DailyMed - ENOXAPARIN SODIUM- enoxaparin sodium injection". dailymed.nlm.nih.gov. Archived from the original on 2015-10-19. ... However a human's response to enoxaparin might be different than that of a small animal, therefore enoxaparin should be used ...
Enoxaparin Sodium 1.5 mg/kg q.d. SC n = 298 %. Enoxaparin Sodium 1 mg/kg q12h SC n = 559 %. Heparin aPTT Adjusted IV Therapy n ... enoxaparin sodium (UNII: 8NZ41MIK1O) (enoxaparin - UNII:E47C0NF7LV) enoxaparin sodium. 100 mg in 1 mL. ... Enoxaparin Sodium 1.5 mg/kg q.d. SC n (%). Enoxaparin Sodium 1 mg/kg q12h SC n (%). Heparin aPTT Adjusted IV Therapy n (%). ... Enoxaparin Sodium 40 mg q.d. SC. Enoxaparin Sodium 30 mg q12h SC. Heparin 15,000 U/24h SC. Placebo q12h SC. ...
enoxaparin sodium (UNII: 8NZ41MIK1O) (enoxaparin - UNII:E47C0NF7LV) enoxaparin sodium. 100 mg in 1 mL. ... enoxaparin sodium (UNII: 8NZ41MIK1O) (enoxaparin - UNII:E47C0NF7LV) enoxaparin sodium. 150 mg in 1 mL. ... Enoxaparin Sodium 1.5 mg/kg daily subcutaneously. n (%) Enoxaparin Sodium 1 mg/kg q12h subcutaneously. n (%) Heparin aPTT ... enoxaparin sodium 30 MG in 0.3 ML Prefilled Syringe. PSN. 2. 854228. 0.3 ML Enoxaparin sodium 100 MG/ML Prefilled Syringe. SCD ...
Enoxaparin is not known to be harmful if used during pregnancy. It does not cross the placenta and so does not enter the babys ... The use of enoxaparin has not been studied in women who are breastfeeding. However, it is unlikely to pass into breast milk and ... Enoxaparin can prevent and treat these types of abnormal blood clots. It works by inactivating thrombin in the clotting process ... Clexane (enoxaparin): an anticoagulant used to prevent blood clots. Everything you need to know about Clexane injections ...
Royalty revenues from enoxaparin sodium injection in Q3 were disappointing and reflected the market realities of a more ... CEO Craig Wheeler commented: "Royalty revenues from enoxaparin sodium injection in Q3 were disappointing and reflected the ...
... enoxaparin) includes side effects, uses, drug interactions, dosage, drug pictures, overdose symptoms, and what to avoid. ... Do not inject enoxaparin into a muscle.. Your care provider will show you where on your body to inject enoxaparin. Use a ... Enoxaparin can cause a very serious blood clot around your spinal cord if you undergo a spinal tap or receive spinal anesthesia ... Enoxaparin can cause a very serious blood clot around your spinal cord if you undergo a spinal tap or receive spinal anesthesia ...
... evidence of a lack of anti-coagulant activity in the serum of breastfed infants whose mothers were treated with Enoxaparin. The ... We do not have alternatives for Enoxaparin Sodium since it is relatively safe. ... Postpartum osteoporosis and vertebral fractures in two patients treated with enoxaparin during pregnancy. Osteoporos Int. 2014 ... Breast-feeding is possible in case of maternal treatment with enoxaparin]. Arch Pediatr. 1996 Abstract ...
Enoxaparin has been shown to inhibit smooth muscle cell proliferation at high tissue concentrations.31 32 33 However, it has ... The purpose of enoxaparin delivery during predilation was to have an antithrombotic agent in place at the time of the initial ... Enoxaparin suppresses thrombin formation and activity during cardiopulmonary bypass in baboons. J Thorac Cardiovasc Surg. 1998; ... enoxaparin. Stenting of discrete lesions in large coronary arteries results in lower restenosis rates than conventional ...
Conclusion: The results conclusively showed that the enoxaparin manufactured by Rovi is equivalent to the reference enoxaparin ... Participants were sequentially and randomly administered single subcutaneous injections of enoxaparin 100 mg manufactured by ... equivalence of a biosimilar enoxaparin to the reference drug, and to assess its safety and tolerability in healthy volunteers. ... Rovi (test; Madrid, Spain) and Clexane® (enoxaparin 100 mg manufactured by Sanofi, reference) separated by a 1-week washout ...
... What is this medicine?. ENOXAPARIN (ee nox a PA rin) is used after knee, hip, or abdominal surgeries to ... an unusual or allergic reaction to enoxaparin, heparin, pork or pork products, other medicines, foods, dyes, or preservatives ...
Apixaban vs Enoxaparin for Postoperative Prophylaxis: Safety of an Oral Alternative for the Prevention of Venous ... Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.. *Oral apixaban for the treatment of venous ... Apixaban vs Enoxaparin for Postoperative Prophylaxis: Safety of an Oral Alternative for the Prevention of Venous ... "Apixaban Vs Enoxaparin for Postoperative Prophylaxis: Safety of an Oral Alternative for the Prevention of Venous ...
... enoxaparin), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, ... encoded search term (enoxaparin%20%28Lovenox%29) and enoxaparin (Lovenox) What to Read Next on Medscape. Medscape Consult. ... If last enoxaparin was given 8-12 hr before balloon inflation, an IV bolus of 0.3 mg/kg should be administered ... Continue enoxaparin for a minimum of 5 days and until a therapeutic oral anticoagulant effect has been achieved (INR 2.0-3.0) ...
Enoxaparin for 7 days was better than unfractionated heparin for 2 days for reducing death and MI but not bleeding in STEMI ... Massel D. Enoxaparin for 7 days was better than unfractionated heparin for 2 days for reducing death and MI but not bleeding in ... Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med. 2006;354:1477- ... In patients with ST-elevation myocardial infarction (STEMI), how does enoxaparin compare with unfractionated heparin (UFH) as ...
Efficacy and Safety of Tenecteplase in Combination With the Low-Molecular-Weight Heparin Enoxaparin or Unfractionated Heparin ... Efficacy and Safety of Tenecteplase in Combination With the Low-Molecular-Weight Heparin Enoxaparin or Unfractionated Heparin ... Efficacy and Safety of Tenecteplase in Combination With the Low-Molecular-Weight Heparin Enoxaparin or Unfractionated Heparin ... Efficacy and Safety of Tenecteplase in Combination With the Low-Molecular-Weight Heparin Enoxaparin or Unfractionated Heparin ...
... enoxaparin,Sodium,Injection),to,5,Weeks,is,More,Effective,Than,10,Days,for,Reducing,the,Risk,of,Venous,Thromboembolism,(VTE),in ... prophylaxis with enoxaparin, a low-molecular-weight heparin (LMWH) with the standard regimen of enoxaparin (10 plus or minus 4 ... About Clexane(R) / Lovenox(R) (enoxaparin). Lovenox(R) is a unique chemical entity in a class of antithrombotic agents known as ... The objective of the Exclaim study was to assess the superiority of enoxaparin prophylaxis given for 28 plus or minus 4 days ...
enoxaparin ligand page. Quantitative data and detailed annnotation of the targets of licensed and experimental drugs. ...
We would like to compare the use of enoxaparin and tinzaparin in pregnant women who have a previous history of venous ... We propose to compare the coagulation profiles of enoxaparin and tinaparin. We will use TEG and anti Xa activity to monitor ...
Member of Farmavita.net offers dossier in European CTD format for Enoxaparin sodium, 100 mg/ml, pre-filled syringes of 20/40/60 ...
The efficacy and safety of enoxaparin vs unfractionated heparin in prevention of deep vein thrombosis in elective cancer ...
Enoxaparin is a FDA pregnancy category B drug which means enoxaparin is not expected to cause harm to an unborn baby when used ... Enoxaparin is in the low molecular weight heparin family of medications. Enoxaparin was first made in 1981 and approved for ... "DailyMed - ENOXAPARIN SODIUM- enoxaparin sodium injection". dailymed.nlm.nih.gov. Archived from the original on 2015-10-19. ... However a humans response to enoxaparin might be different than that of a small animal, therefore enoxaparin should be used ...
Enoxaparin Injection: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Before taking enoxaparin,. *tell your doctor and pharmacist if you are allergic to enoxaparin, heparin, any other drugs, or ... Continue to use enoxaparin even if you feel well. Do not stop taking enoxaparin without talking to your doctor. ... Enoxaparin is used to prevent blood clots in the leg in patients who are on bedrest or who are having hip replacement, knee ...
Aspirin/clopidogrel/enoxaparin sodium. Pituitary apoplexy: case report. Reactions Weekly volume 1170, page9(2007)Cite this ... Aspirin/clopidogrel/enoxaparin sodium. React. Wkly. 1170, 9 (2007). https://doi.org/10.2165/00128415-200711700-00018 ...
Enoxaparin reduced portal vein thrombosis in patients with advanced cirrhosis, thereby reducing risk for clinical ... for enoxaparin, and at 2 years, 48% compared with 24% - again favoring enoxaparin," said Dr. Villa. ... After 1 year of treatment, there were 6 PVT events in the placebo group (n = 36) and no events in the enoxaparin group. At the ... A total of 70 cirrhotic patients (Child-Pugh score of B7 to C10) were randomized in a 1:1 ratio to treatment with enoxaparin or ...
Read the side effects of Enoxaparin as described in the medical literature. In case of any doubt consult your doctor or ... Enoxaparin - Information. Enoxaparin prevents blood clots in patients who are on bed rest or who are having orthopedic surgery ... Side effect(s) of Enoxaparin Read the side effects of Enoxaparin as described in the medical literature. In case of any doubt ...
Easy-to-read patient leaflet for Enoxaparin Multi-Dose Vials. Includes indications, proper use, special instructions, ... What do I need to tell my doctor BEFORE I take Enoxaparin Multi-Dose Vials?. For all patients taking this medicine (enoxaparin ... How is this medicine (Enoxaparin Multi-Dose Vials) best taken?. Use this medicine (enoxaparin multi-dose vials) as ordered by ... If you have an allergy to enoxaparin or any other part of this medicine (enoxaparin multi-dose vials). ...
Enoxaparin is prescription medication used for as prophylaxis treatment of deep vein thrombosis (DVT). Learn about side effects ... Generic Name: Enoxaparin. Drug Class: Anticoagulants, Cardiovascular; Anticoagulants, Hematologic. What Is Enoxaparin and How ... This medication contains enoxaparin. Do not take Lovenox if you are allergic to enoxaparin or any ingredients contained in this ... Enoxaparin has serious interactions with at least 68 different drugs.. Enoxaparin has moderate interactions with at least 135 ...
Enoxaparin (Lovenox) is an injectable drug used to prevent and treat blood clots. Learn about side effects, warnings, dosage, ... Enoxaparin is a self-injectable drug.. Why its used. Enoxaparin is used to thin your blood. It keeps your blood from forming ... Enoxaparin side effects. Enoxaparin injectable solution may cause pain or bruising of the skin at the site of the injection. ... What is enoxaparin?. Enoxaparin injectable solution is a prescription drug thats available as the brand-name drug Lovenox. ...
A Major Drug Interaction exists between Acetylsalicylic Acid and enoxaparin. View detailed information regarding this drug ... Talk to your doctor before using enoxaparin together with aspirin. Combining these medications can increase the risk of ... Drug Interactions between Acetylsalicylic Acid and enoxaparin. This report displays the potential drug interactions for the ...
Enoxaparin - Last updated on December 7, 2019. ©2019 Memorial Sloan Kettering Cancer Center. ...
2 patient evaluations for Enoxaparin taken for the purpose of blood clot 6 members have decided to share their profiles only ...
Find the most comprehensive real-world treatment information on Enoxaparin at PatientsLikeMe. 11 patients with fibromyalgia, ... bipolar I disorder or psoriasis currently take Enoxaparin. ... Currently taking Enoxaparin Duration. Patients. This item is ... Stopped taking Enoxaparin Duration. Patients. This item is relevant to you: Less than 1 month 40 * 40 ... Why patients stopped taking Enoxaparin. Multiple reasons could be selected. Reason. Patients. This item is relevant to you: ...
The pharmacokinetics of subcutaneous enoxaparin in end-stage renal disease.. Brophy DF1, Wazny LD, Gehr TW, Comstock TJ, Venitz ... The pharmacokinetics of enoxaparin were determined from plasma antifactor Xa activity concentrations, and various multiple-dose ... Enoxaparin should be used cautiously in patients with end-stage renal disease. [Pharmacotherapy. 2001] ... All subjects received a single dose of enoxaparin sodium 1 mg/kg subcutaneously and had serial plasma antifactor Xa activity ...
Farajun Y, Zarfati D, Abramov L, Livoff A, Bornstein J. Enoxaparin treatment for vulvodynia: a randomized controlled trial. ... The investigators hypothesize that injections of Low molecular weight heparin (LMWH) [enoxaparin] will reduce pain in women ...
Enoxaparin Sodium Injection) may treat, side effects, dosage, drug interactions, warnings, patient labeling, reviews, and ... Enoxaparin is a low molecular weight heparin which has antithrombotic properties.. Pharmacodynamics. In humans, enoxaparin ... No long-term studies in animals have been performed to evaluate the carcinogenic potential of enoxaparin. Enoxaparin was not ... Following intravenous dosing, the total body clearance of enoxaparin is 26 mL/min. After intravenous dosing of enoxaparin ...
Enoxaparin (Lovenox), a low-molecular-weight heparin, proved more effective than unfractionated heparin for preventing ... In a head-to-head study of 1,762 stroke patients unable to walk unassisted, enoxaparin was 43% more effective at preventing ... Enoxaparin reduced the risk of venous thromboembolism by 43% compared with unfractionated heparin (68 [10%] versus 121 [18%]; ... Tell patients who ask that in this study, a low-molecular-weight drug, enoxaparin (Lovenox), was found more effective than ...
Treatment consisted of an injection of 11.7 mg/kg body weight of enoxaparin per day (Clexane) in addition to methylprednisolone ... To investigate the preventive effect of enoxaparin on steroid-related osteonecrosis, we used male New Zealand white rabbits. ... This finding suggests that cotreatment with enoxaparin has the potential to prevent steroid-associated osteonecrosis. ... Enoxaparin treatment decreases glucocorticoid-induced necrotic changes of osteocytes. The application of enoxaparin with ...
... enoxaparin sodium injection) refers to the medical reasons for why Lovenox is used and recommended as a treatment. ...
... Følgende præparater indeholder indholdsstoffet Enoxaparin: Præparat. Dispenseringsform/styrke. Andre ...
573 with enoxaparin [5.7 percent]; hazard ratio in the fondaparinux group, 1.01; 95 percent confidence interval, 0.90 to 1.13 ... Enoxaparin versus unfractionated heparin in ST-elevation myocardial infarction. [N Engl J Med. 2006] ... 1308, P=0.06). The rate of major bleeding at nine days was markedly lower with fondaparinux than with enoxaparin (217 events [ ... Fondaparinux is similar to enoxaparin in reducing the risk of ischemic events at nine days, but it substantially reduces major ...
Enoxaparin is also used if you are unable to get out of bed because of a serious illness. In addition, enoxaparin is used to ... Enoxaparin is used to prevent deep venous thrombosis, a condition in which harmful blood clots form in the blood vessels of the ... Enoxaparin may cause bleeding problems. This risk is higher if you have a catheter in your back for pain medicine or anesthesia ... Enoxaparin is used together with warfarin to treat acute deep vein thrombosis with or without pulmonary embolism. It is also ...
Enoxaparin is also used if you are unable to get out of bed because of a serious illness. In addition, enoxaparin is used to ... Enoxaparin is used to prevent deep venous thrombosis, a condition in which harmful blood clots form in the blood vessels of the ... Enoxaparin is used together with warfarin to treat acute deep vein thrombosis with or without pulmonary embolism. It is also ...
Fondaparinux bests enoxaparin overall in ACS.(Cardiovascular Medicine) by Internal Medicine News; Health care industry Health ... general Clinical trials Coronary heart disease Drug therapy Enoxaparin Dosage and administration Fibrinolytic agents ... They received subcutaneous injections of 2.5 mg of fondaparinux once daily for up to 8 days, or enoxaparin at 1 mg/kg twice ... MLA style: "Fondaparinux bests enoxaparin overall in ACS.." The Free Library. 2005 International Medical News Group 19 Nov. ...
They were randomized to rivaroxaban or to enoxaparin plus either warfarin or acenocoumarol for a treatment period of three, six ... In the comparator arm, patients received weight-adjusted enoxaparin until the international normalized ratio was 2.0 or greater ... with enoxaparin plus a vitamin K antagonist during treatment of as long as 12 months.. In a parallel study patients with ...
Patients assigned to enoxaparin.. Drug: Enoxaparin Patients will be receive 6 months of subcutaneous enoxaparin (1 mg/kg BID ... Enoxaparin Versus Aspirin in Patients With Cancer and Stroke. The safety and scientific validity of this study is the ... In addition, the study aims to compare the effects, good and/or bad, of enoxaparin with those of aspirin on patients with ... These patients are routinely treated with medicines that thin their blood, including enoxaparin or aspirin. However, it is ...
  • What is enoxaparin (Lovenox)? (emedicinehealth.com)
  • What are the possible side effects of enoxaparin (Lovenox)? (emedicinehealth.com)
  • What is the most important information I should know about enoxaparin (Lovenox)? (emedicinehealth.com)
  • What should I discuss with my healthcare provider before using enoxaparin (Lovenox)? (emedicinehealth.com)
  • How should I use enoxaparin (Lovenox)? (emedicinehealth.com)
  • Some medicines, such as insulin or the blood-thinner enoxaparin (Lovenox), are injected only under the skin. (alberta.ca)
  • The anticoagulant enoxaparin - sold under the brand name Lovenox - which is associated with superior COVID-19 outcomes, is more likely to be given to Caucasian patients. (netscape.com)
  • These highlights do not include all the information needed to use enoxaparin sodium injection safely and effectively. (nih.gov)
  • See full prescribing information for enoxaparin sodium injection. (nih.gov)
  • Clexane injection contains the active ingredient enoxaparin, which is a type of medicine called a low molecular weight heparin. (netdoctor.co.uk)
  • Clexane injection contains the enoxaparin, which stops blood clots forming inside the blood vessels. (netdoctor.co.uk)
  • CEO Craig Wheeler commented: "Royalty revenues from enoxaparin sodium injection in Q3 were disappointing and reflected the market realities of a more competitive multi-player dynamic. (yahoo.com)
  • We are a leading Wholesale Trader of enoxaparin sodium injection, imipenem and cilastatin injection, 40 mg enoxaparin sodium injection, vasopressin injection, esmolol injection and propofol injection from Mumbai, India. (shomhealthcare.com)
  • Effect of venous line administration of Low Molecular Weight Heparin, Enoxaparin compared to manufacturer recommended arterial line administration on four hour post injection anti-Xa level in patients on Haemodialysis or Haemodiafiltration through arterio-venous access and using high-flux membrane - A randomised cross-over trial. (anzctr.org.au)
  • Enoxaparin will be administered as a bolus injection either through the arterial or venous line. (anzctr.org.au)
  • Enoxaparin is given by subcutaneous injection in fixed dosages and does not require blood level monitoring. (emaxhealth.com)
  • Madrid, Spain) and Clexane ® (enoxaparin 100 mg manufactured by Sanofi, reference) separated by a 1-week washout period. (dovepress.com)
  • In tirofiban-treated patients with acute coronary syndrome undergoing percutaneous coronary intervention, fondaparinux presented similar efficacy for ischemia events as enoxaparin. (biomedcentral.com)
  • Optimal timing between the administration of enoxaparin sodium and neuraxial procedures is not known. (nih.gov)
  • The DCRI researchers led two multi-national clinical trials and conducted one meta-analysis comparing unfractionated heparin to enoxaparin, the newer low molecular weight heparin. (emaxhealth.com)
  • Anti-Xa level four hour post administration of equal dose of enoxaparin. (anzctr.org.au)
  • Plasma Anti-Xa level will be compared between both groups for the same dose of enoxaparin. (anzctr.org.au)
  • abstract = "{\textcopyright} 2017 Steunstichting ESOT Venous thromboembolism (VTE) is a frequent complication after solid organ transplantation (SOT) and, specifically, after lung transplantation (LT). The objectives of this study were to evaluate prophylaxis with enoxaparin and to describe risk factors for VTE after LT. We retrospectively reviewed the clinical records of 333 patients who underwent LT in our institution between 2009 and 2014. (uab.cat)
  • We compared two consecutive cohorts: one that received enoxaparin only during post-transplant hospital admissions and a second cohort that received 90-day extended prophylaxis with enoxaparin. (uab.cat)
  • The results conclusively showed that the enoxaparin manufactured by Rovi is equivalent to the reference enoxaparin in all primary and secondary PK/PD parameters, as required by the European Medicines Agency to grant marketing authorization to a biosimilar low molecular-weight heparin. (dovepress.com)
  • Arterial line versus venous line administration of Low Molecular Weight Heparin, Enoxaparin for prevention of thrombosis in the extracorporeal blood circuit of patients on Haemodialysis or Haemodiafiltration through arterio-venous access and using high-flux membrane- A randomised cross-over trial. (anzctr.org.au)
  • Experimental - administration of Low Molecular Weight Heparin, Enoxaparin in to the venous line of extracorporeal blood circuit in patients on Haemodialysis or Haemodiafiltration through Arterio-Venous access and using high-flux membrane. (anzctr.org.au)
  • To demonstrate the pharmacokinetic/pharmacodynamic (PK/PD) equivalence of a biosimilar enoxaparin to the reference drug, and to assess its safety and tolerability in healthy volunteers. (dovepress.com)
  • Lipponer, Christine (2012): Perioperative Antikoagulation mit einem niedermolekularen Heparin (Enoxaparin) in gewichtsadaptierter Dosis bei arteriellen Rekonstruktionen. (uni-ulm.de)
  • Enoxaparin and Fondaparinux are potential anticoagulants which are used peri-operatively in the management of patients with Acute Coronary Syndrome (ACS). (biomedcentral.com)
  • Enoxaparin can cause a very serious blood clot around your spinal cord if you undergo a spinal tap or receive spinal anesthesia (epidural), especially if you have a genetic spinal defect, a history of spinal surgery or repeated spinal taps, or if you are using other drugs that can affect blood clotting, including blood thinners or NSAIDs ( ibuprofen , Advil , Aleve , and others). (emedicinehealth.com)
  • Ultimately we find that there are no great differences in outcomes or side effects between the two drugs, so given the ease of use of enoxaparin, it would appear to be preferred. (emaxhealth.com)
  • 1 ml in 1 syringe of Enoxaparin Sodium, a human prescription drug labeled by Fresenius Kabi Usa, Llc. (ndclist.com)
  • DURHAM, N.C. - Three studies led by Duke Clinical Research Institute (DCRI) cardiologists have shown that the ease and convenience of a newer formulation of the blood-thinner heparin, called enoxaparin, appear to make it the drug of choice for treating patients with suspected heart attacks. (emaxhealth.com)
  • Patients from 2008 to 2012 receiving enoxaparin were included, provided 2 or more steady state AXAL were obtained within 30 days and that the enoxaparin was prescribed for treatment rather than prophylaxis. (wustl.edu)
  • Much has changed in the treatment of patients with acute coronary syndromes since the first studies comparing enoxaparin with unfractionated heparin, according to DCRI cardiologist John Petersen, M.D., first author of the meta-analysis published in JAMA. (emaxhealth.com)
  • Given that we as are being more aggressive in the treatment of acute coronary syndromes, we wanted see how enoxaparin fared in the 'new world' of cardiology. (emaxhealth.com)
  • Mit der vorliegenden Untersuchung wurde eine sichere Dosierungsempfehlung für die Antikoagulation mit Enoxaparin in der perioperativen Phase bei gefäßchirurgischen Rekonstruktionen in der arteriellen Strohmbahn gefunden. (uni-ulm.de)
  • Even during a follow up period of 30 days or a midterm follow up, major and minor bleeding still significantly favored fondaparinux in comparison to enoxaparin. (biomedcentral.com)
  • The incidence of a major adverse cerebrovascular or cardiovascular event (10.9 % vs 12.6 %, P = 0.433) and cardiac mortality (0.5 % vs 1.5 %, P = 0.116) were generally lower in the fondaparinux group than in the enoxaparin group, although the differences were not significant. (biomedcentral.com)
  • Enoxaparin has comparable and sometimes better mortality outcomes than the older formulation, found the researchers. (emaxhealth.com)
  • Mortality rates were 41% in patients who got unfractionated heparin and 15% in patients administered enoxaparin, researchers reported on Tuesday on medRxiv ahead of peer review. (netscape.com)
  • Enoxaparin is also used to prevent blood vessel complications in people with certain types of angina ( chest pain ) or heart attack . (emedicinehealth.com)
  • Enoxaparin is in the low molecular weight heparin family of medications. (wikipedia.org)
  • Enoxaparin is made from heparin. (wikipedia.org)
  • Protamine sulfate is less effective at reversing enoxaparin compared to heparin, with a maximum neutralization of approximately 60% of the anti-factor Xa effect. (wikipedia.org)
  • tell your doctor and pharmacist if you are allergic to enoxaparin, heparin, any other drugs, or pork products. (medlineplus.gov)
  • November 15, 2011 (San Francisco, California) - A new treatment regimen with the low-molecular-weight heparin enoxaparin reduced the incidence of portal vein thrombosis (PVT), leading to fewer events of clinical decompensation and enhanced survival in patients with advanced cirrhosis, according to data presented here at The Liver Meeting 2011: American Association for the Study of Liver Diseases 62nd Annual Meeting. (medscape.com)
  • Clexane injection contains the active ingredient enoxaparin, which is a type of medicine called a low molecular weight heparin. (netdoctor.co.uk)
  • If you have ever had a low platelet count during past use of this medicine (enoxaparin multi-dose vials), heparin , or another drug like this one. (drugs.com)
  • Enoxaparin is a form of the anticoagulant (anti-clotting) heparin. (patientslikeme.com)
  • Lovenox is a sterile aqueous solution containing enoxaparin sodium, a low molecular weight heparin . (rxlist.com)
  • Enoxaparin sodium is obtained by alkaline depolymerization of heparin benzyl ester derived from porcine intestinal mucosa . (rxlist.com)
  • Lovenox 100 mg/mL Concentration contains 10 mg enoxaparin sodium (approximate anti-Factor Xa activity of 1000 IU [with reference to the W.H.O. First International Low Molecular Weight Heparin Reference Standard]) per 0.1 mL Water for Injection. (rxlist.com)
  • Tell patients who ask that in this study, a low-molecular-weight drug, enoxaparin (Lovenox), was found more effective than unfractionated heparin. (medpagetoday.com)
  • SAN ANTONIO, Tex., April 20 -- Enoxaparin (Lovenox), a low molecular-weight heparin, proved more effective than unfractionated heparin for preventing potentially fatal leg and lung clots after acute ischemic stroke, researchers reported. (medpagetoday.com)
  • In a head-to-head study of 1,762 stroke patients unable to walk unassisted, enoxaparin was 43% more effective at preventing venous thromboembolism than unfractionated heparin, David G. Sherman, M.D., of the University of Texas here, and colleagues reported in the Apil 21 issue of The Lancet . (medpagetoday.com)
  • The results of this study, Dr. Sherman concluded, suggest that for patients with acute ischemic stroke, enoxaparin is preferable to unfractionated heparin for venous thromboembolism prophylaxis in view of its better clinical benefits-to-risk ratio and convenience of once daily administration. (medpagetoday.com)
  • Within 48 hours of symptoms, 666 patients were given enoxaparin (40 mg subcutaneously) once daily for 10 days, while 669 got unfractionated heparin (5,000 U subcutaneously) every 12 hours, for 10 days (range for all, six to 14 days). (medpagetoday.com)
  • A post-hoc analysis of major subgroups -- diabetes, obesity, previous stroke, age, for example -- showed consistent reductions of venous thromboembolism risk for enoxaparin compared with unfractionated heparin. (medpagetoday.com)
  • Enoxaparin versus unfractionated heparin in ST-elevation myocardial infarction. (nih.gov)
  • In North America, it is priced lower than enoxaparin, further increasing its attractiveness as a therapeutic alternative to low-molecular-weight heparin, which has been shown superior to unfractionated heparin in the treatment of ACS, the physician said. (thefreelibrary.com)
  • Enoxaparin is a low molecular weight fraction of the anticoagulant heparin. (tinnitusformula.com)
  • The results conclusively showed that the enoxaparin manufactured by Rovi is equivalent to the reference enoxaparin in all primary and secondary PK/PD parameters, as required by the European Medicines Agency to grant marketing authorization to a biosimilar low molecular-weight heparin. (dovepress.com)
  • Purpose of the study: To determine whether low molecular weight heparin (LMWH) enoxaparin decreases the rate of maternal and perinatal composite morbidity in women who previously had a severe preeclampsia that occurred at less than 34 weeks' gestation. (clinicaltrials.gov)
  • To assess the risk of intracranial hemorrhage associated with the administration of therapeutic doses of low molecular heparin, we performed a matched, retrospective cohort study of 293 cancer patients with brain metastasis (104 with therapeutic enoxaparin and 189 controls). (bloodjournal.org)
  • ROVI has successfully completed the decentralized procedure to apply for marketing authorization for a low-molecular-weight heparin (enoxaparin biosimilar) in twenty-six European Union countries. (rovi.es)
  • In randomized clinical trials enoxaparin in non ST-elevation acute coronary syndromes (NSTE-ACS) has been shown to be more effective than unfractionated heparin in preventing the combined endpoint of death and myocardial infarction. (springer.com)
  • Aim of the present study was to determine the clinical impact of optimized antithrombotic therapy with enoxaparin, clopidogrel and aspirin compared to standard therapy with unfractionated heparin (UFH) and aspirin in NSTE-ACS in clinical practice. (springer.com)
  • Randomized trial comparing: 1) enoxaparin with unfractionated heparin (UFH), and 2) tirofiban with placebo for treatment of acute myocardial infarction (MI) patients not eligible for reperfusion. (acc.org)
  • The Safety and Efficacy of Subcutaneous Enoxaparin Versus Intravenous Unfractionated Heparin and Tirofiban Versus Placebo in the Treatment of Acute ST-Segment Elevation Myocardial Infarction Patients Ineligible for Reperfusion (TETAMI). (acc.org)
  • We prospectively compared the safety of enoxaparin sodium, a low-molecular-weight heparin (LMWH), with unfractionated heparin (UFH), both of which were administered within 24 hours of cesarean section. (go.jp)
  • Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. (annals.org)
  • In patients with ST-elevation myocardial infarction (STEMI), how does enoxaparin compare with unfractionated heparin (UFH) as adjunctive therapy with fibrinolysis for reducing death or MI? (annals.org)
  • Methods and Results- In the prehospital setting, 1639 patients with ST-elevation myocardial infarction were randomly assigned to treatment with tenecteplase and either (1) intravenous bolus of 30 mg enoxaparin (ENOX) followed by 1 mg/kg subcutaneously BID for a maximum of 7 days or (2) weight-adjusted unfractionated heparin (UFH) for 48 hours. (ahajournals.org)
  • Objective: The goal of this study was to determine the cost-effectiveness of the low-molecular-weight heparin (LMWH) enoxaparin versus warfarin for the universal prophylaxis of DVT and associated long-term complications in US patients undergoing total hip replacement surgery (THRS). (rti.org)
  • The aim of this study was to examine the effect of dry onion extract and low molecular weight (LMW) heparin (enoxaparin) on the cytokine production. (termedia.pl)
  • Low-molecular-weight heparin (enoxaparin) was a kind gift from Welding (Hamburg, Germany). (termedia.pl)
  • Enoxaparin is a low molecular weight heparin commonly used in patients with acute coronary syndromes that reduces their risk of death or myocardial infarction (MI). (cardiologyonline.com)
  • Enoxaparin ( enoxaparin sodium), a low molecular weight heparin,is used to treat and prevent deep vein thrombosis. (scirp.org)
  • Enoxaparin sodium is an important variety of low-molecular-weight heparin preparations, which is originally developed by Aventis (later merged with Sanofi). (giichinese.com.tw)
  • Therefore, we investigated the efficacy and safety of the low-molecular weight heparin enoxaparin in preventing DVT in patients with brain tumors. (ovid.com)
  • The efficacy and safety of enoxaparin vs unfractionated heparin in prevention of deep vein thrombosis in elective cancer surgery. (diva-portal.org)
  • ORLANDO, Florida, December 12 (HSMN NewsFeed) --sanofi-aventis announced today that the results of the PREVAIL (Prevention of VTE after Acute Ischemic Stroke with LMWH Enoxaparin) study presented at the 48th American Society of Hematology (ASH) annual meeting in Orlando demonstrated a significant 43% reduction in venous thromboembolism (VTE) events with enoxaparin vs. unfractionated heparin (UFH) in medically-ill patients who suffered an acute ischemic stroke. (salesandmarketingnetwork.com)
  • The international ATOLL study sponsored by the Assistance Publique - Hopitaux de Paris showed that enoxaparin reduced the composite of death, complication of myocardial infraction, procedure failure or major bleeding by 17% in comparison with standard heparin (p=0.07) in acute heart-attack (STEMI) patients managed with primary Percutaneous Coronary Intervention (PCI). (thailand4.com)
  • Patients received either intravenous administration of 0.5 mg/kg enoxaparin (Clexane/Lovenox(R)) without anticoagulation monitoring/dose adjusted or standard UFH (unfractionated heparin) prior to primary Percutaneous Coronary Intervention, a procedure also referred as angioplasty and stenting. (thailand4.com)
  • The ATOLL (Acute STEMI Treated with primary angioplasty and intravenous enoxaparin Or UFH to Lower ischemic and bleeding events at short and Long-term follow-up) study is the first randomised, head-to-head comparison between unfractionated heparin (UFH) and Clexane/Lovenox(R) (enoxaparin) in primary angioplasty in subjects with ST-segment elevation myocardial infarction (STEMI). (thailand4.com)
  • Rovi's enoxaparin sodium is a biosimilar to Sanofi-Aventis' Lovenox® and Clexane ® , which is an anticoagulant medication that belongs to low molecular weight heparin class. (hikma.com)
  • The Thrombolysis in Myocardial Infarction (TIMI) 11A trial compared the safety and tolerability of two weight-adjusted regimens of subcutaneous injections of enoxaparin, a low molecular weight heparin, in patients with unstable angina/non-Q wave myocardial infarction (NQMI). (timi.org)
  • Enoxaparin is low molecular weight heparin (LMWH) and was first approved for medical use in 1993 and is derived from heparin. (statpearls.com)
  • Enoxaparin is a type of low molecular weight heparin (LMWHs) with a mean molecular weight of 4000 to 5000. (statpearls.com)
  • [4] Enoxaparin has less activity against factor IIa (thrombin) compared to unfractionated heparin. (statpearls.com)
  • Enoxaparin has an advantage over heparin because of its bioavailability. (statpearls.com)
  • Enoxaparin is a low molecular weight heparin (LMWH) with antithrombotic properties. (drugspi.org)
  • Enoxaparin, like any LMWH, is derived by depolymerization of unfractionated heparin and retains UFH's ability to activate antithrombin and thereby provide anticoagulation. (openanesthesia.org)
  • We recently encountered a 45-year-old male who developed DILI during treatment with enoxaparin, a low-molecular-weight heparin (LMWH), for dural venous thrombosis. (semanticscholar.org)
  • Elevation of hepatic transaminases after enoxaparin use: case report and review of unfractionated and low-molecular-weight heparin-induced hepatotoxicity. (semanticscholar.org)
  • Enoxaparin is created using alkaline beta-eliminative cleavage of the benzyl ester of heparin. (biopharmaspec.com)
  • Enoxaparin is an anticoagulant that helps prevent the formation of blood clots . (emedicinehealth.com)
  • According to the anticoagulant protocol he was treated by subcutaneous injections of enoxaparin 40 mg once a day starting 24 hours after surgery. (scirp.org)
  • Enoxaparin, a widely used anticoagulant, is composed of both anticoagulant and non-anticoagulant fragments. (edu.au)
  • The potential therapeutic value of enoxaparin in LP must be explored using well-designed clinical trials, combined with experimental studies that focus on identifying the anti-inflammatory fragments of enoxaparin and elucidating the mechanism of action of these non-anticoagulant fragments. (edu.au)
  • By allowing maintenance of the same anticoagulant throughout patient management from the emergency room or the ambulance to the catheterization laboratory then to the Cardiac Care Unit, without anticoagulation monitoring, enoxaparin is securing and simplifying the treatment strategy' he added. (thailand4.com)
  • When enoxaparin is used, there is no utility in checking the aPTT (the drug has a wide therapeutic window, and aPTT does not correlate with the anticoagulant effect). (medscape.com)
  • Although enoxaparin is used to prevent blood clots it is necessary to remember that pregnancy alone can raise a woman's risk of clotting. (wikipedia.org)
  • Enoxaparin is used to prevent blood clots in the leg in patients who are on bedrest or who are having hip replacement, knee replacement, or stomach surgery. (medlineplus.gov)
  • Enoxaparin prevents blood clots in patients who are on bed rest or who are having orthopedic surgery of the hip replacement, knee replacement, or large intestinal surgery. (medindia.net)
  • Enoxaparin can prevent and treat these types of abnormal blood clots. (netdoctor.co.uk)
  • Enoxaparin is used to prevent blood clots in people who are hospitalized or at home. (healthline.com)
  • In addition, enoxaparin is used to prevent blood clots from forming in the arteries of the heart during certain types of chest pain and heart attacks. (mayoclinic.org)
  • Enoxaparin is used to treat or prevent a type of blood clot called deep vein thrombosis ( DVT ), which can lead to blood clots in the lungs ( pulmonary embolism ). (emedicinehealth.com)
  • Treatment of unstable angina (UA) and non-Q-wave myocardial infarction (NQMI), administered concurrently with aspirin DVT prophylaxis in knee replacement surgery DVT prophylaxis in hip replacement surgery DVT prophylaxis in abdominal surgery Treatment of DVT with or without pulmonary embolism Treatment of DVT inpatient, with ST-segment elevation myocardial infarction (STEMI) Enoxaparin has predictable absorption, bioavailability, and distribution therefore monitoring is not typically done. (wikipedia.org)
  • Talk to your doctor before using enoxaparin together with aspirin. (drugs.com)
  • In addition, the study aims to compare the effects, good and/or bad, of enoxaparin with those of aspirin on patients with cancer and recent stroke. (clinicaltrials.gov)
  • To answer this question, the investigators propose to conduct a multicenter prospective randomized trial that will compare two groups in parallel: a group where women will have an association of enoxaparin 4000 U/day and aspirin 100 mg/day and another group where women would have only aspirin 100 mg/day. (clinicaltrials.gov)
  • First group treated with aspirin 100 mg/day until 35 weeks' gestation and enoxaparin subcutaneous 4000 UI/day until delivery. (clinicaltrials.gov)
  • After randomization at first prenatal visit patients will be allocated to aspirin-enoxaparin or aspirin alone as mentioned above. (clinicaltrials.gov)
  • This prospective audit reports pregnancy outcomes, anticoagulation complications, and anti-Xa levels in women with mechanical heart valves who were treated with therapeutic enoxaparin plus aspirin during pregnancy. (nih.gov)
  • Between 1997 and 1999, 11 women with mechanical heart valves were treated with enoxaparin, 1 mg/kg twice daily, and aspirin, 100 to 150 mg daily during 14 pregnancies. (nih.gov)
  • We analyzed data of 2,956 consecutive patients with NSTE-ACS and either antithrombotic therapy with enoxaparin, clopidogrel and aspirin or with aspirin and UFH, which were prospectively enrolled in the acute coronary syndromes registry (ACOS) from July 2000 until the end of November 2002. (springer.com)
  • After adjustment for baseline characteristics and PCI the combined endpoint of hospital death and non-fatal reinfarctions was lower in the group with optimized antithrombotic therapy including clopidogrel, enoxaparin and aspirin compared to the control-group with aspirin and UFH (odds ratio 0.30, 95% confidence interval 0.16-0.53). (springer.com)
  • In clinical practice optimized antithrombotic therapy with aspirin, clopidogrel and enoxaparin in NSTE-ACS is associated with a reduction in the combined endpoint of death and non-fatal reinfarctions compared to standard therapy with aspirin and UFH without increase in major bleeding complications. (springer.com)
  • Tell your doctor you use this medicine (enoxaparin multi-dose vials) before you have a spinal or epidural procedure. (drugs.com)
  • Some time may need to pass between the use of this medicine (enoxaparin multi-dose vials) and your procedure. (drugs.com)
  • What do I need to tell my doctor BEFORE I take Enoxaparin Multi-Dose Vials? (drugs.com)
  • If you have an allergy to enoxaparin or any other part of this medicine (enoxaparin multi-dose vials). (drugs.com)
  • Do not give this medicine (enoxaparin multi-dose vials) to a newborn or infant. (drugs.com)
  • This is not a list of all drugs or health problems that interact with this medicine (enoxaparin multi-dose vials). (drugs.com)
  • You must check to make sure that it is safe for you to take this medicine (enoxaparin multi-dose vials) with all of your drugs and health problems. (drugs.com)
  • What are some things I need to know or do while I take Enoxaparin Multi-Dose Vials? (drugs.com)
  • Tell all of your health care providers that you take this medicine (enoxaparin multi-dose vials). (drugs.com)
  • Very bad and sometimes deadly bleeding problems have happened with this medicine (enoxaparin multi-dose vials). (drugs.com)
  • If you are 65 or older, use this medicine (enoxaparin multi-dose vials) with care. (drugs.com)
  • If you are pregnant or you get pregnant while taking this medicine (enoxaparin multi-dose vials), call your doctor right away. (drugs.com)
  • How is this medicine (Enoxaparin Multi-Dose Vials) best taken? (drugs.com)
  • Use this medicine (enoxaparin multi-dose vials) as ordered by your doctor. (drugs.com)
  • All subjects received a single dose of enoxaparin sodium 1 mg/kg subcutaneously and had serial plasma antifactor Xa activity concentrations measured over 24 hours. (nih.gov)
  • The pharmacokinetics of enoxaparin were determined from plasma antifactor Xa activity concentrations, and various multiple-dose regimens were simulated. (nih.gov)
  • However, elderly patients are more likely to have bleeding problems and age-related kidney disease, which may require an adjustment in the dose for patients receiving enoxaparin, especially those who weigh less than 45 kilograms (99 lb). (mayoclinic.org)
  • Patients will be receive 6 months of subcutaneous enoxaparin (1 mg/kg BID with a maximum starting dose of 100 mg BID. (clinicaltrials.gov)
  • The anti-factor Xa (anti-Xa) level was checked once after 4-6 hours of the third or fourth dose of enoxaparin (at steady state). (dovepress.com)
  • Enoxaparin daily dose used for prophylaxis indications ranged from 0.3 to 0.85 mg/kg and from 0.31 to 2.25 mg/kg in case of certain treatment indications. (dovepress.com)
  • On the other hand, most patients (88.5%) who received enoxaparin for prophylaxis indications were on a fixed 40 mg/d dose. (dovepress.com)
  • 1) Enoxaparin, 30 mg IV bolus + 1 mg/kg SC for 2-8 days + tirofiban, 10 microgram/kg IV bolus + 0.10 microgram/kg/min IV infusion 2) enoxaparin (above dose) + placebo, 3) UFH + tirofiban (above dose), and 4) UFH + placebo. (acc.org)
  • To compare the effectiveness and safety of fixed-dose enoxaparin and adjusted-dose warfarin in preventing venous thromboembolism after knee arthroplasty. (annals.org)
  • Patients were randomly assigned to receive enoxaparin (30 mg subcutaneously every 12 hours) or adjusted-dose warfarin (international normalized ratio, 2.0 to 3.0). (annals.org)
  • This increased bleeding seen with enoxaparin is thought to be due to the drug s intrinsic properties associated with the inhibition of thrombin in combination with a current recommended dose of enoxaparin that may be too high. (cardiologyonline.com)
  • The optimal dose of enoxaparin in patients with arterial disorders has not been established. (timi.org)
  • During the in-hospital phase, patients received either 1.25 mg/kg body weight (dose tier 1) or 1.0 mg/kg (dose tier 2) of enoxaparin subcutaneously every 12 h. (timi.org)
  • Prophylactic anticoagulation with low dose enoxaparin: is the subcutaneous route appropriate in the critically ill? (biomedcentral.com)
  • 5. The method according to claim 4, wherein the daily dose of enoxaparin is 40 mg. (patentsencyclopedia.com)
  • Largely secondary to its smaller molecular size, enoxaparin binds less to plasma proteins, macrophages, and endothelial cells, thereby promoting a more reliable dose-response relationship and longer plasma half-life compared to UFH. (openanesthesia.org)
  • Additionally, dose-adjustment of enoxaparin can be troublesome in severely obese patients. (openanesthesia.org)
  • Following a therapeutic weight-based dose of enoxaparin given subcutaneously, the anti-Xa activity peaks at 4 hours and this is the advised time to conduct monitoring assays. (openanesthesia.org)
  • Comparison of fondaparinux and enoxaparin in acute coronary syndromes. (nih.gov)
  • We therefore assessed whether fondaparinux would preserve the anti-ischemic benefits of enoxaparin while reducing bleeding. (nih.gov)
  • Fondaparinux is similar to enoxaparin in reducing the risk of ischemic events at nine days, but it substantially reduces major bleeding and improves long term mortality and morbidity. (nih.gov)
  • Fondaparinux versus enoxaparin in acute coronary syndromes. (nih.gov)
  • OASIS-5: how do fondaparinux and enoxaparin compare in patients with acute coronary syndromes? (nih.gov)
  • Fondaparinux was noninferior to enoxaparin for death, MI, and refractory ischemia but reduced bleeding in angina and non-STEMI. (nih.gov)
  • Fondaparinux bests enoxaparin overall in ACS. (thefreelibrary.com)
  • S.v. Fondaparinux bests enoxaparin overall in ACS. (thefreelibrary.com)
  • STOCKHOLM -- The antithrombotic agent fondaparinux provided similar short-term efficacy compared with enoxaparin, but dramatically greater safety and superior long-term outcomes in the largest-ever clinical trial involving patients with acute coronary syndrome. (thefreelibrary.com)
  • They received subcutaneous injections of 2.5 mg of fondaparinux once daily for up to 8 days, or enoxaparin at 1 mg/kg twice daily. (thefreelibrary.com)
  • their 30-day combined rate of death, MI, and major bleeding was 10.1% with enoxaparin, compared with 8.1% with fondaparinux, a highly significant (20%) difference. (thefreelibrary.com)
  • Among 1,732 patients who underwent PCI within the first 24 hours, the major bleeding rate was 4.7% with enoxaparin and 39% lower with fondaparinux. (thefreelibrary.com)
  • The clinical implications of OASIS-5 are that for every 1,000 patients with acute coronary syndrome (ACS) treated with fondaparinux instead of enoxaparin, there will be 10 fewer cases of death or MI, 4 fewer strokes, and 25 fewer major bleeds, according to Dr. Yusuf, professor of medicine and director of the Population Health Research Institute at McMaster University, Hamilton, Ont. (thefreelibrary.com)
  • The trial found that fondaparinux is similar to enoxaparin in reducing the risk of ischemic coronary events and it significantly decreases major bleeding. (cardiologyonline.com)
  • These participants were randomly assigned to receive fondaparinux 2.5mg daily and placebo enoxaparin bid or to receive enoxaparin 1mg per kg of body weight bid and placebo fondaparinux daily. (cardiologyonline.com)
  • These findings suggest that fondaparinux, while having a similar efficacy to enoxaparin, has significantly less bleeding, which is associated with lower long-term mortality and morbidity. (cardiologyonline.com)
  • Consequently, the authors recommend using fondaparinux as an alternative to enoxaparin in the short-term care of patients with acute coronary syndromes. (cardiologyonline.com)
  • The study had 95% power for rejecting the hypothesis that the rate of recurrence with fondaparinux would be 3.5% higher than with enoxaparin. (acpjc.org)
  • In this large and methodologically rigorous trial, Büller and colleagues compared fondaparinux with enoxaparin in patients with acute DVT and concluded that the rates of recurrent DVT and bleeding were virtually identical. (acpjc.org)
  • Objectives This study sought to evaluate the relative safety and efficacy of fondaparinux and enoxaparin in patients with acute coronary syndromes (ACS) treated with glycoprotein (GP) IIb/IIIa inhibitors or thienopyridines. (onlinejacc.org)
  • Background The OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial showed that fondaparinux reduced major bleeding by 50% compared with enoxaparin while preserving similar efficacy. (onlinejacc.org)
  • Methods Patients with ACS (n = 20,078) were randomized as a part of the OASIS 5 trial to receive either fondaparinux or enoxaparin. (onlinejacc.org)
  • Conclusions In patients receiving GP IIb/IIIa inhibitors or thienopyridines, fondaparinux reduces major bleeding and improves net clinical outcome compared with enoxaparin. (onlinejacc.org)
  • 430 patients were included in the fondaparinux group (2.5 mg/d), and 464 were included in the enoxaparin group (1 mg/kg twice daily). (biomedcentral.com)
  • Fondaparinux and enoxaparin were applied for 3-7 days. (biomedcentral.com)
  • One-year data were available for 422 patients in the fondaparinux group and for 453 in the enoxaparin group. (biomedcentral.com)
  • The incidence of a major adverse cerebrovascular or cardiovascular event (10.9 % vs 12.6 %, P = 0.433) and cardiac mortality (0.5 % vs 1.5 %, P = 0.116) were generally lower in the fondaparinux group than in the enoxaparin group, although the differences were not significant. (biomedcentral.com)
  • In tirofiban-treated patients with acute coronary syndrome undergoing percutaneous coronary intervention, fondaparinux presented similar efficacy for ischemia events as enoxaparin. (biomedcentral.com)
  • Cite this: Enoxaparin Ups Survival in Cirrhotic Portal Vein Thrombosis - Medscape - Nov 15, 2011. (medscape.com)
  • Enoxaparin is prescription medication used for as prophylaxis treatment of deep vein thrombosis ( DVT ), which may lead to pulmonary embolism (PE) in patients undergoing abdominal surgery , hip replacement surgery (during and following hospitalization), knee replacement surgery and in medical patient who are at risk for thromboembolic complications due to severe restricted mobility during acute illness . (rxlist.com)
  • Enoxaparin is used together with warfarin to treat acute deep vein thrombosis with or without pulmonary embolism. (mayoclinic.org)
  • Patients with symptomatic deep-vein thrombosis (DVT) had a recurrence rate of 2.1% with rivaroxaban compared with 3% with enoxaparin plus a vitamin K antagonist during treatment of as long as 12 months. (medpagetoday.com)
  • In 48 months of enoxaparin treatment, one woman who had a documented valve thrombosis when she presented at 8 weeks' gestation also had a valve thrombosis at 20 weeks' gestation. (nih.gov)
  • Successful pregnancy outcome may be achieved with therapeutic subcutaneous enoxaparin, but its efficacy at preventing valve thrombosis remains uncertain. (nih.gov)
  • Conclusions: Enoxaparin prophylaxis for four weeks after surgery for abdominal or pelvic cancer is safe and significantly reduces the incidence of venographically demonstrated thrombosis, as compared with enoxaparin prophylaxis for one week. (lu.se)
  • Enoxaparin sodium can not only prevent DVT (deep vein thrombosis) and pulmonary embolism but also treat venous thrombosis. (giichinese.com.tw)
  • These results, consistent with the results of the STEEPLE(3) study showing the superior safety profile of enoxaparin versus UFH in patients undergoing elective PCI, contribute to building a more complete picture of the use of enoxaparin in all thrombosis settings, and further add to the 50,000 patients who have participated in cardiovascular trials of enoxaparin to date. (bankkaufmann.com)
  • The FDA filing is based on the results of the landmark ExTRACT-TIMI 25 trial (Enoxaparin and Thrombosis Reperfusion for Acute Myocardial InfarCtion Treatment, Thrombolysis In Myocardial Infarction - Study 25), which was published in the April 2006 edition of the New England Journal of Medicine and presented at the 2006 American College of Cardiology's 55th Annual Scientific Session. (salesandmarketingnetwork.com)
  • Pregnant woman on enoxaparin should be monitored on a regular basis for bleeding and/or "excessive anticoagulation" especially when the delivery date is approaching. (wikipedia.org)
  • To evaluate the degree of anticoagulation achieved with different enoxaparin dosing regimens used in obese and morbidly obese patients in a hospital setting in Jordan. (dovepress.com)
  • Patients in the PCI-ExTRACT-TIMI 25 study received adjunctive anticoagulation therapy with either enoxaparin or UFH in a blinded fashion during fibrinolysis and underwent subsequent PCI. (bankkaufmann.com)
  • These results indicate that adding enoxaparin for anticoagulation supports a practice pattern in which PCI is performed at some time following fibrinolytic administration. (bankkaufmann.com)
  • Moreover, not only does enoxaparin provide a seamless transition to the catheterisation laboratory without the need for additional antithrombin inhibition, it also removes the need for monitoring in the catheterisation laboratory, thereby offering an attractive and more practical alternative to the cumbersome and uncertain administration requirements of UFH anticoagulation. (bankkaufmann.com)
  • Because of its more predicable pharmacokinetics, enoxaparin is given in fixed doses for thromboprophylaxis and total body weight (TBW)-adjusted doses for full anticoagulation, typically without laboratory monitoring. (openanesthesia.org)
  • Apixaban for Thromboprophylaxis: An Alternative to Enoxaparin? (physiciansweekly.com)
  • For thromboprophylaxis in women undergoing surgery for gynecologic cancer, oral apixaban-an oral factor Xa antagonist-may be an easier-to-take and less painful alternative to subcutaneous enoxaparin, offering both safety and comparable efficacy, according to a recent study published in JAMA Network Open . (physiciansweekly.com)
  • In fact, researchers found no differences between apixaban and enoxaparin in major bleeding rates, clinically relevant nonmajor bleeding rates, and venous thromboembolic events. (physiciansweekly.com)
  • Guntupalli and colleagues assessed and compared major bleeding rates and clinically relevant nonmajor bleeding events over 90 days with apixaban or enoxaparin. (physiciansweekly.com)
  • We hypothesized that extended prophylaxis with apixaban would be safe and more effective than short-term prophylaxis with enoxaparin. (ovid.com)
  • A total of 6528 subjects underwent randomization, 4495 of whom could be evaluated for the primary efficacy outcome - 2211 in the apixaban group and 2284 in the enoxaparin group. (ovid.com)
  • In medically ill patients, an extended course of thromboprophylaxis with apixaban was not superior to a shorter course with enoxaparin. (ovid.com)
  • Apixaban was associated with significantly more major bleeding events than was enoxaparin. (ovid.com)
  • Apixaban, an orally active factor Xa inhibitor, might be as effective, have lower bleeding risk, and be easier to use than is enoxaparin. (blogspot.com)
  • Major or clinically relevant non-major bleeding occurred in 4% of patients receiving apixaban and 5% of treated with enoxaparin. (blogspot.com)
  • The authors concluded that apixaban 2·5 mg twice daily, starting on the morning after total knee replacement, offers a convenient and more effective orally administered alternative to 40 mg per day enoxaparin, without increased bleeding. (blogspot.com)
  • This trial compared apixaban 2.5 mg orally twice daily (n=1528) starting 12-24 hours after wound closure to enoxaparin 40 mg subcutaneously once daily (n=1529) starting 12 hours before surgery for 10-14 days. (clotcare.com)
  • In the ADVANCE-2 trial, apixaban displayed superiority compared to enoxaparin 40 mg daily for DVT prophylaxis following knee replacement surgery. (clotcare.com)
  • However, results of the ADVANCE-1 trial, apixaban 2.5 mg daily compared to enoxaparin 30 mg twice daily, did not meet pre-specified non-inferiority criteria 2 . (clotcare.com)
  • Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement. (clotcare.com)
  • A recent meta-analysis 5 of 16 randomized clinical trials that included 38, 747 patients was done to compare the new oral anticoagulants (dabigatran, rivaroxaban and apixaban) with enoxaparin for prophylaxis against VTE after total hip or knee replacement. (mhmedical.com)
  • To compare the efficacy and safety of the drugs, the researchers undertook a large, 15-nation multinational randomized study (PREVAIL), sponsored by Sanofi-Aventis, maker of enoxaparin. (medpagetoday.com)
  • The aim of the study was to determine whether enoxaparin was associated with superior efficacy and safety compared to UFH in the PCI setting. (bankkaufmann.com)
  • The present trial showed that treatment with enoxaparin did not provide added benefit to treatment with UFH. (acc.org)
  • The pre-specified main secondary efficacy endpoint showed that treatment with enoxaparin resulted in a statistically significant 40% reduction of patients' death, recurrent acute coronary syndrome or urgent revascularisation. (thailand4.com)
  • To evaluate the pharmacokinetics of enoxaparin in end-stage renal disease (ESRD), and determine if dosage reduction is necessary to maintain antifactor Xa activity concentrations within the therapeutic range. (nih.gov)
  • When various therapeutic regimens were simulated to predict average steady-state antifactor Xa activity, standard enoxaparin dosages of 1 mg/kg subcutaneously every 12 hours and 1.5 mg/kg every 24 hours resulted in average steady-state concentrations within the therapeutic range. (nih.gov)
  • Enoxaparin is another therapeutic option for these patients, but adherence in the outpatient prophylactic setting is low. (physiciansweekly.com)
  • The administration of multiple therapeutic doses of enoxaparin has been shown to result in significantly elevated anti-Xa levels in subjects with CrCl under 30 mL/min. (openanesthesia.org)
  • Any patient hospitalized in 2016 and 2018 and who received a prescription for enoxaparin or tinzaparin was included in the study. (bmj.com)
  • In 2018 we studied 2,061 prescriptions for 629 patients (591 patients had only enoxaparin, 10 only tinzaparin and 28 had a switch). (bmj.com)
  • The aim of this study consists in the analysis of prescriptions of enoxaparin and tinzaparin and the anti-Xa levels before/after the dissemination of the protocol during the summer of 2017. (bmj.com)
  • Results In 2016 2,246 prescriptions for 630 patients were analyzed (601 patients had only enoxaparin, 7 only tinzaparin and 22 had a switch between the two heparins). (bmj.com)
  • Conclusions The overall results show an improvement in the prescription of enoxaparin and tinzaparin and in the anti-Xa levels since the dissemination of the protocol for prescribing physicians. (bmj.com)
  • To investigate the preventive effect of enoxaparin on steroid-related osteonecrosis, we used male New Zealand white rabbits. (hindawi.com)
  • Results: When the analysis included only the short-term consequences of DVT, therapy with enoxaparin resulted in a net cost of $133 per patient and a net increase of 0.04 quality-adjusted life-years (QALYs) per patient. (rti.org)
  • A total of 70 cirrhotic patients (Child-Pugh score of B7 to C10) were randomized in a 1:1 ratio to treatment with enoxaparin or placebo. (medscape.com)
  • After 1 year of treatment, there were 6 PVT events in the placebo group (n = 36) and no events in the enoxaparin group. (medscape.com)
  • There was a significant difference in the enoxaparin group both after 1 year of treatment and at the 2-year follow-up. (medscape.com)
  • This translates into a probability of developing decompensation of 25% at 1 year with no treatment, compared with 10% for enoxaparin, and at 2 years, 48% compared with 24% - again favoring enoxaparin," said Dr. Villa. (medscape.com)
  • One patient in the enoxaparin group discontinued treatment because of asymptomatic thrombocytopenia. (medscape.com)
  • Farajun Y, Zarfati D, Abramov L, Livoff A, Bornstein J. Enoxaparin treatment for vulvodynia: a randomized controlled trial. (clinicaltrials.gov)
  • In the comparator arm, patients received weight-adjusted enoxaparin until the international normalized ratio was 2.0 or greater for two consecutive days and after a minimum of five days of treatment. (medpagetoday.com)
  • After treatment with enoxaparin, he recovered more than 25 dB hearing in the affected ear. (tinnitusformula.com)
  • In acute MI patients not eligible for reperfusion, treatment with enoxaparin will result in improved 30-day outcomes compared with UFH treatment. (acc.org)
  • Randomized controlled trial (The Enoxaparin and Thrombolysis Reperfusion for Acute MI Treatment-Thrombolysis in MI [ExTRACT-TIMI] 25 study). (annals.org)
  • The objective of EXCLAIM study was to assess the superiority of enoxaparin prophylaxis given for 28 plus or minus 4 days versus placebo, both following an initial treatment with enoxaparin for 10 plus or minus 4 days, to reduce VTE events rate. (bio-medicine.org)
  • The goal of the study was to compare SCD, enoxaparin, and combined SCD/enoxaparin prophylaxis among patients requiring surgery for treatment of intracranial neoplasms. (ovid.com)
  • We believe that these results are important because they show that enoxaparin is a more effective treatment for STEMI patients undergoing PCI compared to UFH, the current standard treatment of care. (bankkaufmann.com)
  • With regard to major bleeding risk, the main safety endpoint, no difference was observed in the two treatment groups (respectively 4.9% and 4.5% for UFH and enoxaparin). (thailand4.com)
  • A Phase III trial is now underway to test the benefits of uninterrupted treatment with enoxaparin during both the in-hospital and outpatient treatment phases. (timi.org)
  • Enoxaparin, who developed severe abdominal pain and hypovolemia after three days of treatment. (jcdr.net)
  • 6. The method according to claim 1, wherein said patient undergoes mechanical thromboprophylaxis during the treatment period with enoxaparin. (patentsencyclopedia.com)
  • 8. The method according to claim 1, wherein the risk of death is reduced at day 30 after the start of the treatment with enoxaparin. (patentsencyclopedia.com)
  • PHARMAC is pleased to announce the approval of an agreement with Sanofi-Aventis New Zealand Limited (Sanofi) for the listing of plerixafor for use in DHB hospitals, along with price reductions for enoxaparin sodium. (pharmac.govt.nz)
  • One mg of enoxaparin is equal to 100 units of anti-Xa activity. (statpearls.com)
  • Compared to UFH, enoxaparin has lower anti-IIa activity relative to anti-Xa activity and this translates into a reduced effect on the aPTT. (openanesthesia.org)
  • We propose to compare the coagulation profiles of enoxaparin and tinaparin. (isrctn.com)
  • In humans, Enoxaparin potentiates preferentially the inhibition of coagulation Factor Xa. (drugspi.org)
  • By activating antithrombin III, enoxaparin preferentially potentiates the inhibition of coagulation factors Xa and IIa. (salvavidaspharmaceutical.com)
  • The effect of these agents on standard coagulation tests will vary (minimal for enoxaparin) as will the effect of protamine neutralization, which is incomplete for enoxaparin. (openanesthesia.org)
  • Bleeding is less common with enoxaparin, so factor Xa monitoring is not necessary in most cases. (statpearls.com)
  • Factor Xa catalyzes the conversion of prothrombin to thrombin, so Enoxaparin' s inhibition of this process results in decreased thrombin and ultimately the prevention of fibrin clot formation. (drugspi.org)
  • Methods: We conducted a double-blind, multicenter trial in which patients undergoing planned curative open surgery for abdominal or pelvic cancer received enoxaparin (40 mg subcutaneously) daily for 6 to 10 days and were then randomly assigned to receive either enoxaparin or placebo for another 21 days. (lu.se)
  • The patients were randomly divided into 2 groups,54 cases in Rivaroxaban group and 48 cases in enoxaparin sodium group. (cnki.com.cn)
  • The pharmacokinetics of subcutaneous enoxaparin in end-stage renal disease. (nih.gov)
  • Based on antifactor Xa activity, ESRD has little effect on the pharmacokinetics of enoxaparin, and dosing adjustments are unnecessary. (nih.gov)
  • There were no differences observed in the cumulative incidence of intracranial hemorrhage at 1 year in the enoxaparin and control cohorts for measurable (19% vs 21%, Gray test P=0.97, HR 1.02 [90%CI 0.66-1.59]), significant (21% vs 22%, P=0.87), and total (44% vs 37%, P=0.13) intracranial hemorrhages. (bloodjournal.org)
  • The study was terminated because of the increased incidence of adverse events in the enoxaparin-treated groups. (ovid.com)
  • 30mL/min has been shown to be associated with an increased incidence of major hemorrhage in patients treated with enoxaparin. (openanesthesia.org)